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SUM M ARY
This thesis is a report on nine studies o f patients w ith  malignant
hypertension who were seen in Glasgow between 1968 and 1983 (Studies 1-3, 
7-9) and in Johannesburg in 1983 and 1984 (Study 6).
1. C lin ica l features o f 139 patients w ith  malignant hypertension.
The firs t study is a description of 139 patients w ith  malignant
hypertension (70 males, mean age 45 years) who were admitted to the Blood 
Pressure Unit in Glasgow between 1968 and 1983 (108 cases) or to the 
Renal Unit at the Royal In firm ary in Glasgow between 1979 and 1983 (31 
cases). Average in it ia l blood pressure was 233+27/145+18 (SD) mmHg. A ll 
patients had b ila tera l re tina l haemorrhages and exudates, thus satisfying the 
WHO crite ria  fo r the diagnosis o f malignant hypertension. N inety-six also 
had papiiloedema. F ifty -s ix  (40%) patients had a possible underlying cause 
fo r their hypertension, particu la rly  renovascular disease (19), chronic 
glomerulonephritis (13) and in te rs titia l nephropathy (12). A ll but three
patients had symptoms, the commonest o f which were headache and visual 
upset. Other c lin ica l features included serum creatinine >120 umol/1 in
79%, electrocardiographic evidence o f le f t  ventricular hypertrophy in 86%, 
cardiac fa ilure in 30% and neurological complications in 17%. We conclude 
tha t malignant hypertension should be suspected in severely hypertensive 
patients who complain o f symptoms, particu la rly  headache and visual upset. 
Having confirmed the diagnosis by fundal examination, a fu ll diagnostic 
evaluation, including renal arteriography, is indicated.
2. Retinal changes in the diagnosis o f malignant hypertension.
The second analysis concerns the importance o f d iffe ren t re tina l 
changes in the diagnosis o f malignant hypertension. I t  is in two parts. 
Four observers reviewed 56 photographs of fundi from patients w ith  severe
hypertension and grade III or IV retinopathy. Complete agreement on the 
presence or absence o f haemorrhages and exudates was recorded in 93% and 
95% o f cases respectively. Opinion on papilloedema was divided, however, 
w ith  agreement between all four observers in 61% o f cases only. In the 
second part o f the study, the re lation between d iffe ren t retinal changes and 
survival was examined by life  tables. Ten year survival was 46% in 
patients w ith  b ila tera l haemorrhages and exudates alone (n= 43) and 48% 
when papilloedema was present as well (n= 96). M ultivaria te  analysis 
confirmed that papilloedema was not related to survival in these patients. 
These results suggest tha t papilloedema is an unreliable physical sign, and 
tha t i t  does not adversely a ffec t prognosis in hypertensive patients who 
already have b ila te ra l re tina l haemorrhages and exudates.
3. C igarette smoking may predispose to malignant hypertension.
The th ird  analysis tests the possibility tha t cigarette smoking may 
predispose to the malignant phase in susceptible subjects. The smoking 
habits o f 82 patients w ith  malignant hypertension were compared w ith  those 
of subjects in three control groups matched fo r age and sex. Sixty-seven 
(82%) patients w ith  malignant hypertension were smokers, compared w ith  41 
(50%) and 71 (43%) patients in two control groups with non malignant 
hypertension, and 43 people (52%) in a general population survey. The 
excess of smokers in the malignant phase group was significant fo r both 
sexes separately and together, fo r a ll forms o f smoking combined and fo r 
cigarette  smoking alone. I t  is concluded tha t hypertensive patients who 
smoke are more like ly  to develop the malignant phase than those who do 
not.
4. Relation between oral contraceptives and malignant hypertension.
The fourth  paper examines the relation between the oral
contraceptive p ill and malignant hypertension in women o f childbearing age. 
T h irty -fou r o f the women in the main analysis were aged 15-44 years, and 
o f these 11 were taking oral contraceptives at presentation. A ll had normal 
blood pressure before starting the p ill. In four, the in te rva l between the 
s ta rt o f oral contraceptives and the diagnosis of malignant phase was less 
than 4 months, and in 8 no other cause fo r the hypertension was found. 
Underlying renal disease and renal fa ilure were less common among p ill 
users than among non-users w ith  malignant hypertension who were o f sim ilar 
age. No p ill user became normotensive a fte r w ithdrawal o f the p ill, but 
blood pressure was well controlled (diastolic <90 mmHg) in three patients on 
one drug only. By contrast, a ll 23 non-users needed two or more 
antihypertensive drugs to control blood pressure. Ten year survival was 90% 
among p ill users and 50% among non-users. These results suggest that oral 
contraceptives may be a common cause o f malignant hypertension in women 
of childbearing age. I f  the p ill is stopped and underlying renal disease can 
be excluded, the long-term prognosis fo r such patients is excellent.
5. Abnormal haemostasis and malignant hypertension.
The f if th  analysis is a test o f the hypothesis tha t low grade 
coagulopathy is a necessary step in the transition from  the benign to 
malignant phase. Eighteen patients w ith  malignant hypertension, 18 healthy 
controls and 18 patients w ith  non-malignant hypertension were studied. 
Both groups of controls were matched fo r age, sex and smoking habit w ith 
patients in the malignant phase, and the hypertensive controls were selected 
in addition to have sim ilar blood pressure, serum creatinine and renal 
pathology. Malignant hypertensives had higher levels o f fibrinogen, a2 
macroglobulin and plasminogen than non-malignant hypertensives, and both 
groups of hypertensives had s ign ificantly increased plasma viscosity, blood 
viscosity, fibrinogen, facto r VIIIc and beta-thromboglobulin together w ith
sign ificantly decreased haematocrit, anti-throm bin III and p la te le t counts 
than healthy controls. These results are consistent w ith the hypothesis that 
low grade coagulopathy is im portant in the pathogenesis o f the malignant 
phase, but also raise the possibility tha t abnormal coagulation may be a 
consequence o f the disease.
6. Slow release nifedipine and atenolol as in it ia l treatm ent fo r  malignant 
hypertension.
The sixth study was a tr ia l o f treatm ent. I t  was conducted in the 
Non-European Hospital in Johannesburg where 20 consecutive black patients 
w ith  untreated malignant hypertension were randomised to receive either 
slow release nifedipine 40mg at 0 and 12h, or atenolol lOOmg a t Oh only. 
Baseline blood pressure was 233/142 mmHg in patients given nifedipine and 
226/141 mmHg in patients given atenolol. The rate o f fa ll o f pressure was 
greater a fte r nifedipine, whose maximum hypotensive e ffe c t occurred 4-5 h 
a fte r each dose. Blood pressure decreased more slowly and more enduringly 
a fte r atenolol, although the extent o f the fa ll was the same: A  BP 5h 
a fte r firs t dose nifedipine was 67/41 mmHg; A  BP 16 h a fte r atenolol was 
64/40 mmHg. There were no precipitous fa lls  of pressure, and no patient 
developed focal neurological signs during treatm ent. These results support 
recommendations tha t most patients w ith  malignant hypertension can be 
managed w ithout recourse to parenteral therapy.
7. Malignant hypertension presenting w ith  acute renal fa ilure.
The seventh analysis documents the c lin ica l features and outcome o f 
7 consecutive patients presenting to the Renal Unit at the Royal In firm ary  
in Glasgow w ith malignant essential hypertension and acute renal fa ilu re . 
Only one of these patients was known to  have been hypertensive previously, 
4 were oligo-anuric when firs t seen, and a ll 7 needed dialysis. Good control
of blood pressure was associated w ith  significant recovery o f renal function 
in 5 o f the 7 patients a fte r 10-44 days o f dialysis. Mean serum creatinine 
when last measured was 248 umol/1 (range 125-350 umol/1) a fte r an average 
o f 24 months (range 15-62 months) fo llow  up. The only feature which 
appeared o f value in predicting recovery of renal function was the presence 
of tubular regeneration on renal biopsy. This was present in 4 o f 5 biopsies 
from patients who recovered, but in neither o f the two who did not. These 
results confirm  previous reports o f recovery o f renal function in patients 
presenting w ith  malignant essential hypertension and acute renal fa ilu re . 
We have also shown that the proportion o f patients who improve may be 
higher than has been recognised, and that recovery may last several years.
8. Renal outcome in malignant hypertension.
To determine whether there were other circumstances in which long­
term  improvement o f renal function may occur, we examined seria l changes 
in serum creatinine concentration in the main analysis o f 139 patients. 
End-stage renal disease occurred commonly during long-term  follow-up in 
patients w ith  chronic glomerulonephritis (13/13) and in te rs tit ia l nephropathy 
(9/12), irrespective o f blood pressure control, and in patients w ith  essential 
hypertension who presented w ith serum creatinine >300 umol/1 but did not 
require dialysis immediately (11/15). By contrast, renal function tended to 
remain stable or improve slightly in the m ajority o f patients w ith  
renovascular disease, and in patients w ith malignant essential hypertension 
whose serum creatinine was <300 umol/1 when firs t measured. The most 
strik ing improvements in renal function were seen in the 5 patients in this 
series w ith malignant essential hypertension and acute renal fa ilu re , 4 o f 
whom showed sign ificant reduction in serum creatinine a fte r dialysis and 
control of the ir blood pressure. The implications o f these findings are tha t 
in glomerulonephritis and in te rs titia l nephropathy, deterioration o f renal
function represents the natural history of a progressive underlying disease; 
and tha t in malignant essential hypertension, irreversible renal damage w ill 
usually have occurred by the tim e the serum creatinine concentration 
exceeds 300 umol/1 unless acute renal fa ilu re  is superimposed.
9. An analysis of survival in malignant hypertension.
The purpose of the ninth analysis was to determine the extent to 
which the m orta lity  of the 139 patients w ith malignant hypertension 
exceeded that of controls w ith  non-malignant hypertension and the general 
population from which they were derived. Overall survival among patients 
w ith  the malignant phase was 63% at 5 years and 47% at 10 years. 
Patients w ith malignant hypertension were tw ice as like ly  to die as non- 
malignant hypertensives who attended the Glasgow Blood Pressure C lin ic  and 
were matched for age, sex and in itia l diastolic pressure, who in turn  had a 
much reduced life  expectancy when compared w ith an age and sex matched 
general population from the Strathclyde Region. Further analyses showed 
tha t in itia l serum creatinine was strongly related to outcome in patients 
w ith malignant phase, and tha t, proportionately, renal deaths were 3 and 9 
times more common among patients w ith  malignant hypertension than 
controls from the clin ic  and the general population respectively. Despite 
improved survival compared w ith  previous years, renal fa ilu re  remains the 
most serious manifestation o f patients w ith  this disease.
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IN TRO D U CTIO N
Clinicians who manage patients w ith  malignant hypertension have 
witnessed some remarkable changes in recent years. The incidence o f the 
disease appears to have fa llen , at least in the United Kingdom and other 
western countries (1). Reduction o f blood pressure w ith in  minutes by 
parenteral therapy, common practice in the 1950's and 1960's, is no longer 
recommended as a routine procedure, as it  is now recognised that in it ia l 
management is best achieved by one or two drugs given ora lly  (2). Survival 
has improved as a result o f more e ffective antihypertensive drug therapy 
and the increasing ava ilab ility  o f renal dialysis and transplantation (3-6).
Despite these encouraging trends, some d if f ic u lt  areas remain. 
Malignant hypertension continues to be a major problem in developing 
countries and is thought like ly  to stay so fo r some tim e (7). As the disease 
becomes less common in the West, too few doctors see enough o f its 
complications, especially hypertensive encephalopathy, to gain expertise in 
managment (2). Moreover, despite improved survival overall, the prognosis 
fo r patients w ith  impaired renal function remains poor (3-6).
My thesis is concerned prim arily w ith c lin ica l aspects o f malignant 
hypertension. I t  is in two parts. The firs t is a review o f the lite ra tu re , 
and the second is a report on nine studies of patients w ith  malignant 
hypertension who were seen in Glasgow between 1968 and 1983, and in 
Johannesburg in 1983 and 1984.
LITER ATURE SURVEY
Introduction
In th is lite ra tu re  survey, I shall review the diagnosis, pathology, 
pathogenesis, c lin ica l features, management and prognosis o f malignant 
hypertension w ith  particular reference to recently published work.
Diagnostic c r ite ria
The new WHO crite ria  are probably the most useful, namely tha t 
patients should have severe hypertension w ith  b ila tera l re tina l haemorrhages 
and exudates (8). D iastolic blood pressure is usually greater than 130 
mmHg but there is no absolute level above which malignant hypertension 
always develops and below which i t  never occurs. Lower pressures are said 
to be characteristic of patients w ith renal fa ilu re  (9) and o f patients w ith  
eclampsia and acute glomerulonephritis (10), although the la tte r  are both 
uncommon in the UK today. Conversely, patients are frequently seen w ith  
pressures greater than 130 mmHg but w ithout malignant hypertension (11). 
Other features of the disease such as microangiopathic haemolytic anaemia 
(MAHA) and renal fa ilu re  are not always present.
Pathology
Although fibrino id  arterio lar necrosis is usually regarded as the 
histological hallmark of the acute stage o f the disease, it  is not necessarily 
the most sign ificant finding (11,12). Subintimal cellu lar p ro life ra tion  o f the 
interlobular arteries of the kidney is seen more commonly and could be 
im portant in its  own righ t as in tim a l thickening in these small arteries may 
be so great as to occlude the ir lumina (Fig 1). I t  is like ly  tha t vessel 
damage o f this type plays a major part in causing the chronic renal 
ischaemia, and thus the chronic renal fa ilu re , which so often accompanies 
malignant hypertension (11). Neither fib rino id  arterio lar necrosis nor 
subintimal cellu lar proliferation are pathognomonic fo r malignant 
hypertension however, and one or other (and sometimes both) may be seen
FIGURE 1 Renal biopsy in a p a tie n t w ith  m a lignan t hypertension showing 
marked sub in tim a l ce llu la r p ro life ra tio n  o f an in te r lo b u la r a rte ry . The 
vessel lum en appears to  have been com p le te ly  occluded by the th ickened  
in tim a .
in progressive systemic sclerosis, accelerated g ra ft re jection, postpartum
acute renal fa ilu re , haemolytic uraemic syndrome and throm botic
thrombocytopenic purpura (13).
Pathogenesis
The events leading to these pathological changes are s t i l l  not fu lly  
understood. Most accept tha t increased arte ria l pressure is a necessary
feature and tha t the ra te  o f rise o f pressure is more im portant than the
actual level achieved, but opinion then divides on whether there are other
factors capable of determining which patients w ill enter the malignant 
phase. Some have argued that increased pressure is the only fac to r (14), 
others that important roles are played by immunological changes (15),
intravascular coagulation (16,17), cigarette smoking (18-21), the oral
contraceptive p ill (22-30) and vasoactive agents (31,32).
Whichever o f these hypotheses is true, the appearance of a lternating 
bands of constriction and d ila tation in arterioles (the so called "sausage-
string" e ffect) probably heralds the onset of malignant hypertension (11).
I t  is like ly that the dilated segments represent focal fa ilu re  o f the vessel 
wall to resist a rapid rise in intralum inal pressure, and i t  has been shown 
tha t these areas are abnormally permeable to plasma proteins (33). 
Disruption of the vessel wall may then trigger the fo llow ing changes:
insudation of plasma leading to deposition o f fib rin  i.e. fib rino id  necrosis 
(33); platelet aggregation causing release of growth factors which could w ell 
cause the subintimal cellu lar proliferation (34); and activation o f the
coagulation system (16,17). The la tte r may promote fu rthe r deposition o f 
fib rin , not only in the vessel wall, but also w ith in the m icrocircu lation
causing microangiopathic haemolytic anaemia (35).
Epidemiology
Malignant hypertension can occur at any age but rare ly does so in 
patients older than seventy. For the reasons outlined above this may be
because malignant hypertension is most like ly  when severe hypertension 
develops rapidly. I f  instead, blood pressure increases gradually over many 
years to reach very high levels at an advanced age, vasculature may have 
tim e to adapt and so avoid the disruption which leads to subintimal cellu lar 
p ro life ra tion  and fibrinoid necrosis (36).
Most studies (3,5,7,37,38) but not a ll (4,6) show a preponderance o f 
male patients. Also, the disease seems commoner in blacks than whites 
(39,40). Indeed while many authors now consider malignant hypertension to 
be rare among whites (1) it remains a common problem in developing 
countries; in a recent report from Johannesburg no fewer than 2% o f all 
admissions to the medical wards o f the Non-European Hospital were as a 
consequence o f malignant hypertension (7).
Underlying causes
I t  is well recognised tha t patients w ith  malignant hypertension are 
more like ly to have an identifiab le underlying cause fo r the ir high blood 
pressure than are patients w ith non malignant hypertension. Renal and 
renovascular diseases are the causes most commonly found (3-6,41-43) 
although any cause of raised blood pressure can lead to the malignant phase 
i f  the hypertension is severe enough and i f  the blood pressure has risen so 
rapidly as to exceed the autoregulatory capacity o f the re tina l c ircu la tion. 
Even patients w ith Conn's syndrome, a condition previously thought to cause 
only m ild or moderate hypertension, may develop the malignant phase 
(44,45).
C igarette  smoking
The relation between cigarette smoking and hypertension is an 
intriguing one. Epidemiological studies show an inverse relation between 
smoking and blood pressure (46), and yet the act o f smoking causes a 
transient rise in pressure (47). The increased m orta lity  rate among smokers 
w ith  hypertension is also well known (48). That smoking may predispose to
malignant hypertension in patients who are already hypertensive, was firs t 
noted by our group in Glasgow (18) and by colleagues in Birmingham (19). 
Similar findings have subsequently been reported from other centres (20,21). 
Possible mechanisms involved are discussed on page 4 3  o f this thesis.
O ra l c o n tra ce p tive  p i l l
The oral contraceptive p ill causes a small rise in blood pressure in 
most women and a large rise in pressure in a few (49). A number of case 
reports suggest an association between oral contraceptives and malignant 
hypertension (22-30). A causal association seems likely when patients who 
were previously known to be normotensive develop malignant hypertension 
w ithin a few weeks or months of starting oral contraceptives, even i f  as is 
usually the case the ir blood pressure does not fa ll to normal when the p ill 
is stopped. Although i t  is generally agreed that the risk o f malignant 
hypertension is less w ith  low oestrogen p ills , we have seen a patient who 
was previously normotensive and who presented w ith  malignant hypertension 
only eight weeks a fte r starting a p ill containing a low dose (20 ug) o f 
ethinyloestradiol. No other cause fo r her hypertension was found (30). 
C lin ic a l fe a tu re s  o f  m a lig a n t phase hypertens ion .
The wide variety o f c lin ica l features which may occur in malignant 
hypertension are well described in earlier reviews (37,38). Recent onset o f 
headache and visual upset are the commonest complaints (37,38). The 
headache of malignant hypertension is said to be worse in the morning
(50,51) and visual symptoms are generally related in degree to the severity
of the re tina l and optic nerve changes.
Renal fa ilure is the most serious manifestation o f malignant 
hypertension (3-7,52). Despite investigation i t  is often d if f ic u lt  to be
certain in individual patients whether hypertension preceded and perhaps 
caused renal fa ilu re  or whether an underlying renal disorder caused the 
hypertension. Exclusion of renovascular disease is important under these
circumstances since surgical intervention in selected cases may improve both 
blood pressure control and renal function (53). Otherwise, and in the 
m ajority o f cases, the d istinction between prim ary hypertension and primary 
renal disease may yield useful prognostic information (see la te r) but does 
not lead to a change in management.
The heart is commonly involved in malignant hypertension and 
breathlessness due to cardiac fa ilu re  is a frequent c lin ica l manifestation. 
By contrast, ischaemic chest pain occurs rarely (38). L e ft ventricular 
hypertrophy may be prominent (54) but is not a universal finding (55). 
When absent i t  is like ly  that malignant hypertension was o f sudden onset 
and not preceded by a long period of non malignant hypertension.
A number o f neurological complications may occur (56). The most 
serious of these is hypertensive encephalopathy (57-61) whose c lin ica l 
hallmark is altered consciousness, ranging from  agitation to coma. Other 
features include headache, nausea and vom iting, seizures and changing focal 
neurological signs. Fundal examination w ill show re tina l haemorrhages, 
exudates and often papilloedema. D iff ic u lty  may occur in distinguishing 
hypertensive encephalopathy from  cerebral haemorrhage, since severe 
hypertension and ischaemic retinopathy may be present in both conditions. 
As a general ru le patients w ith  major lateralising signs are more like ly  to 
have cerebral haemorrhage (59). The distinction is im portant because the 
rate at which blood pressure should be lowered depends on the specific 
c lin ica l diagnosis.
Gastrointestinal symptoms including anorexia, nausea, vom iting, 
abdominal pain and weight loss occur commonly in malignant hypertension. 
The association o f malignant hypertension and weight loss is not explained 
entire ly by the degree of renal impairment (38). Abdominal pain due to 
acute pancreatitis (62) and small bowel in farction (63) has also been 
recorded.
Other well recognised features o f malignant hypertension include 
microangiopathic haemolytic anaemia (MAHA) and secondary 
hyperaldosteronism. MAHA is thought to arise when red cells are 
fragmented by fib rin  strands laid down w ith in  the m icrocirculation (35,64). 
The diagnosis is based on the presence o f red cell fragmentation on the 
blood film  and, when fu lly  developed, MAHA is associated w ith  low 
haemoglobin, low platelets and increased reticulocytes.
Secondary hyperaldosteronism occurs more frequently than MAHA in 
malignant hypertension, but again i t  is not a universal finding. Renal 
ischaemia secondary to unilateral renal artery disease, or to malignant 
hypertension per se, increases secretion o f renin which, via angiotensin II, is 
the like ly  cause. Hypokalaemia w ill usually be present and is a useful clue 
to the diagnosis. A few patients develop hyponatraemic hypertensive 
syndrome, a vicious cycle in which high blood pressure causes pressure 
natriuresis from the unaffected kidney in unilateral renal artery stenosis. 
This leads to  sodium depletion and fu rthe r elevation o f angiotensin II w ith  
worsening secondary hyperaldosteronism and symptoms o f th irs t, polyuria and 
weight loss (65-70).
D iffe re n tia l diagnosis of retinopathy
Usually the re tina l haemorrhages o f the malignant phase are flam e­
shaped, and the exudates "so ft" (fig  2a). A particu larly flo r id  example is 
shown in fig  2b in which hard exudates, macular stars and papilloedema are 
also present. The pathogenesis o f this form  o f hypertensive retinopathy has 
recently been reviewed (71). Although re tina l haemorrhages and exudates 
are necessary features fo r the diagnosis of malignant hypertension, they are 
not pathognomonic. S im ilar appearances may be seen in diabetes m e llitus 
(fig  2c), re tina l vascular occlusion (figs 2d,2e), raised intracrania l pressure 
(fig  2f), gastrointestinal haemorrhage and a number of haematological 
disorders including anaemia (fig  2g), polycythaemia, leukaemia and
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FIGURE 2 D if fe re n t ia l diagnosis o f hypertensive re tin o p a th y :-
2a - m alignant hypertension showing flam e  shaped haemorrhages and s o ft
exudates.
2b - m alignant hypertension : a p a r tic u la r ly  f lo r id  exam ple showing flam e 
shaped haemorrhages, hard and so ft exudates, m acu lar s ta r and 
papilloedem a.
2c - d iabe tic  re tin op a th y : dot and b lo t haemorrhages and hard exudates are 
ty p ic a l, but occasionally an ischaem ic re tin op a th y  ind istingu ishab le  fro m  th a t 
o f m alignant hypertension may occur.
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FIGURE 2 D if fe re n t ia l diagnosis o f hypertensive re tin op a th y  (continued)
2d - cen tra l re tin a l vein occlusion: an engorged re tin a , w ith  haem orrhage a 
p rom inen t fea tu re , is ty p ic a l.
2e - branch re t in a l vein occlusion: haemorrhages and exudates are lim ite d  to  
the area o f the a ffe c te d  vein.
2 f - raised in tra c ra n ia l pressure: fundus appearance may be s im ila r to  th a t 
o f m alignant hypertension except th a t venous distension is g rea te r.
2g - anaemia: haemorrhage is the main fea tu re  o f th is  fo rm  o f re tin o p a th y , 
in th is  case due to pernicious anaemia.
Waldenstrom’s macroglobulinaemia, a ll of which may produce an ischaemic 
retinopathy (72).
The occurrence o f such sim ilar re tina l changes in these apparently 
unrelated conditions suggests a common pathogenesis which, Pears & 
Pickering have postulated, may be focal hypoxia (73). Thus i t  may be 
useful to consider the re tina as having a lim ited range o f responses to a 
variety o f d iffe rent insults. In the same way that proteinuria may be the 
end result of renal damage from  drugs, toxins, immunological and 
multisystem disease, so may haemorrhages and exudates be the u ltim ate 
expression of hypertension, diabetes and other disorders which a ffec t the 
re tina l circulation. I f  correct, then this model may also explain the 
tendency fo r ischaemic retinopathy to develop at lower blood pressures when 
another disorder capable o f causing ischaemic re tina l damage is present. 
The increased incidence o f exudates in diabetics who are hypertensive, may 
be an example (74), and the well-recognised tendency fo r ischaemic 
retinopathy to develop at lower pressures in renal patients (9) may be 
another, re flecting the combined insults o f hypertension and anaemia.
In it ia l Management of malignant hypertension
The ideal rate of reduction of blood pressure in patients w ith 
malignant hypertension must be a balance between the risks o f inadequate 
and too rapid reduction o f blood pressure. Central to this is the 
phenomenon of autoregulation, the means by which an organ maintains a 
constant blood flow  across a wide range of a rte ria l pressures (fig  3a) (73); 
the brain in particular has l i t t le  capacity to function properly w ithout an 
adequate blood supply, and shows clear autoregulation o f blood flow  (76). In 
uncomplicated malignant hypertension and other forms o f chronic 
hypertension, the range of cerebral autoregulation is reset upwards and 
patients may therefore be less able to compensate fo r a sudden fa ll in 
pressure (fig  3b). Neurological complications, particu larly  cerebral in fa rc tion
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FIGURE 3 Relation between cerebral blood flow  (CBF) and mean a rte ria l 
pressure (MAP). In normotensive man* CBF is maintained at 50ml/100g/m in 
across a wide range of a rte ria l pressure from 63-140 mmHg. In 
hypertension the curve is reset upwards (fig  3a). The lower lim it  o f 
autoregulation is the point at which CBF begins to fa ll,  and the lowest 
tolerated pressure the point at which symptoms o f cerebral ischaemia are 
like ly  to  develop. I t  follows th a t symptoms o f cerebral ischaemia are more 
like ly in hypertensive patients whose blood pressures are reduced too quickly 
(fig  3b). In hypertensive encephalopathy the rate o f rise o f blood pressure 
is thought to have been so rapid as to have exceeded the upper l im it o f 
autoregulation, causing hyperperfusion, cerebral oedema and, i f  untreated 
death (fig  3c). Cerebral autoregulation is lost in the area of an acute 
stroke so that CBF to the ischaemic area becomes pressure dependent (fig  
3d).
in the watershed areas (so called boundary zone in farction) (77,78) and 
blindness (79-82) are w ell recognised. The kidney (83) and spinal cord (84) 
are also susceptible to ischaemic damage when blood pressure is lowered too 
quickly, as a result o f which i t  has been suggested tha t abrupt forms o f 
therapy, particu la rly  injected drugs, be avoided in most cases.
Uncomplicated malignant hypertension
Despite the ir widespread use in the past, there is no evidence tha t 
parenteral drugs are required, and oral agents are usually quite satisfactory 
(85-87). Our current practice is to prescribe atenolol 50-100mg orally or 
nifedipine retard 20-40mg b.d., in itia lly , and usually to  add a d iure tic  on the 
second day. Some authors recommend a d iure tic as part o f the in itia l 
therapy (2), but this has yet to be tested in a c lin ica l tr ia l. In ligh t o f the 
upward sh ift in the autoregulatory curve i t  is probably unwise to attem pt 
fu ll control o f pressure in the firs t week o f treatm ent.
Malignant hypertension w ith  renal failure
I t  used to be recommended that blood pressure be lowered cautiously 
in patients w ith  malignant hypertension and renal fa ilu re  (88) since acute 
loss of renal function resulting from rapid lowering o f blood pressure was 
commonly fa ta l before dialysis became generally available. Opinion has 
since changed such that patients w ith and w ithout renal fa ilu re  are now 
treated s im ila rly . The argument now is tha t renal fa ilu re  w ill worsen unless 
the vessel changes can be made to heal, and tha t this w ill only happen i f  
blood pressure is lowered (89).
Hypertensive heart fa ilu re
Hypertensive heart fa ilu re  differs from  other forms o f cardiac fa ilu re  
in that drug treatm ent not only relieves symptoms, but also removes one o f 
its underlying causes, increased afterload. I t  generally responds to 
conventional treatm ent w ith  diuretics and vasodilators, such as oral 
nifedipine or hydralazine. Reflex tachycardia is rare ly a problem since the
sympathetic nervous system is already maximally stimulated (90).
Hypertensive encephalopathy
Fortunately, hypertensive encephalopathy is extremely uncommon but 
as a consequence of this few doctors in Europe, America and Austra lia  see 
su ffic ient patients to  gain experience in management. The drug o f choice 
is one w ith  rapid onset o f action, producing a predictable fa ll in blood 
pressure, having short duration o f therapeutic e ffec t and preserving cerebral 
blood flow . A drug which fu lf i ls  most o f these crite ria  is nitroprusside (91). 
Although widely recommended, particu lar care has to be taken w ith  this 
drug which is inactivated by ligh t and must be given by constant 
intravenous infusion. The hypotensive e ffec t of nitroprusside is so short 
lived tha t i f  the infusion is interrupted fo r any reason, blood pressure w ill 
very quickly return to baseline levels. Moreover nitroprusside has a tox ic  
metabolite, thiocyanate, which is excreted by the kidneys. Experience in 
Glasgow w ith  labetalol given by intravenous infusion suggests tha t th is m ight 
be a useful alternative treatm ent fo r hypertensive encephalopathy (92). 
Intravenous hydralazine and diazoxide have also been recommended (93). 
Hypertension w ith acute stroke
Regrettably there are s t i l l  no useful data to indicate how best to  
manage increased blood pressure in the presence of an acute stroke (2). 
Special considerations in the hypertensive stroke patient are tha t blood 
pressure is often labile and may fa ll spontaneously, also tha t the 
autoregulatory response is lost loca lly , causing cerebral blood flow  to the 
ischaemic area to become pressure dependent (fig 3d). In patients w ith  
subarachnoid haemorrhage there is the additional risk o f vasospasm. 
Moreover, as already discussed, the distinction between cerebral 
haemorrhage and hypertensive encephalopathy, can sometimes be d if f ic u lt .  
Under the circumstances i t  would seem sensible to withhold antihypertensive 
drugs fo r at least 24-48 hrs i f  d iastolic pressure is less than 120 mmHg.
Treatment should then be in itia ted  cautiously w ith  either a thiazide d iure tic
or a beta blocker. I f  diastolic pressure is greater than 120 mmHg in it ia lly
then the correct course o f action is unclear, although a single oral dose o f 
atenolol 50 mg or nifedipine retard 20 mg would not seem unreasonable in 
the firs t instance. In the unconscious stroke patient, recourse to 
intravenous therapy may be necessary.
E ffe c t of trea tm ent on retinopathy and vision
The risk o f precip itating or worsening visual loss when blood pressure
is lowered too quickly in patients w ith  malignant hypertension has already
been discussed. In most patients, the re tina l lesions clear and vision 
improves w ith  e ffec tive  treatm ent (71). Although a fu lly  formed macular 
star may take a year to  disappear (fig  4a,b) less severe retinopathy clears 
over a period o f 3-6 months (fig  4c). Not every fundus returns completely 
to normal however and two late changes may occasionally be seen: optic  
atrophy and pipe stem sclerosis of the re tina l arterioles (fig  4d). Patients 
who present w ith  severe maculopathy or who develop optic atrophy may 
have residual visual impairment, but otherwise, and in the great m a jo rity  
the prognosis fo r vision is excellent.
E ffe c t of treatm ent on renal function
I t  is useful to  consider short term  changes in renal function and long 
term renal outcome separately. Lawton (94) studied the short term course 
of renal function in malignant hypertensives w ith  renal insufficiency, and 
concluded that when blood pressure is controlled in it ia lly  renal function w ill 
stabilize in 10%, deteriorate progressively in 30% and deteriorate transiently 
before improving in the remainder. Lawton also showed that the la tte r  
group can usually be identified a fte r tw o weeks o f antihypertensive therapy 
and that in the short term , patients w ith  prim ary renal parenchymal disease 
did not have a worse prognosis than those w ithout prim ary renal disease. 
These findings are consistent w ith  current knowledge o f the effects o f
FIGURE 4 Changes th a t may occur in the re tin a  during
tre a tm e n t:
4a and 4b - funda l appearances o f a 15 year o ld g ir l w ith  
m alignant hypertension, taken at p resentation  (fig  4a) and 
a fte r  nine months o f tre a tm e n t ( f ig  4b). Papilloedem a had 
resolved com p le te ly  by th is  tim e  but the m acu lar s ta r was 
s t i l l  present.
4c - reso lu tion  o f funda l changes in a less severe case.
Moving from  top le f t  in c lockw ise  d ire c tio n , these
photographs were taken 3,5,8 and 16 weeks a fte r
presentation . By 16 weeks the papilloedem a and m ost o f 
the haemorrhage and s o ft exudate had disappeared, leaving 
only a sm all trace  o f hard exudate.
4d - o p tic  a trophy and pipe stem  sclerosis o f the re t in a l 
a rte rio les , tw o years a fte r  successful tre a tm e n t fo r 
m a lignan t hypertension.
treatm ent on the hypertensive vascular lesions in the kidney and the 
possible adverse consequences o f reducing renal perfusion pressure.
The question of whether renal function can be improved or 
maintained by treatm ent in the long term  is perhaps more im portant. In 
Study 7, I describe seven patients w ith  malignant essential hypertension and 
acute renal fa ilu re , five  o f whom showed substantial and prolonged 
improvement in renal function fo llow ing a period o f peritoneal dialysis and 
meticulous blood pressure contro l (95). From this experience and that o f 
others (96-108) it  seems like ly  that such patients represent a d istinct 
syndrome, early recognition o f which may allow a more reassuring prognosis 
than was previously considered possible.
For the larger number o f patients w ith  malignant hypertension who do 
not present w ith  acute renal fa ilu re , i t  is now generally accepted tha t renal 
prognosis is determined by the level o f serum creatinine concentration at 
presentation and the presence or absence of underlying renal disease (109- 
115). In Study 8, I describe our experience in Glasgow o f the differences in 
renal outcome when malignant hypertension is superimposed upon renal 
parenchymal disease, renal vascular disease and essential hypertension. 
S u rv iva l
In 1939 Keith et al published life  tables showing tha t five  year 
survival in untreated patients w ith  malignant hypertension was as low as 1% 
(116). Similar findings were reported among untreated patients from  the 
UK (38). With the advent and development of e ffective  antihypertensive 
drug therapy, (52) and more recently the introduction and increasing 
availability  of renal dialysis and transplantation, the prognosis of malignant 
hypertension has improved such tha t in 1979 Gudbrandsson and colleagues 
were able to report a five-year survival of almost 75% (3). Recently 
published data from other centres including Glasgow (4), Melbourne (5) and 
Leicester (6) support this view. A ll authors agree tha t the single most
im portant predictor o f outcome is the degree o f renai impairment at in it ia l 
presentation, and i t  seems like ly  tha t differences in the proportion of 
patients w ith  impaired renal function w ill account fo r many o f the 
remaining differences in results. Survival o f patients w ith  renal function 
tha t is normal or only m ildly impaired may be l i t t le  d iffe ren t from  tha t o f 
non malignant hypertensives matched fo r age, sex and pressure (4).
AIMS OF STUDY 
The nine analyses which fo llow  were developed from  points raised in 
this survey of the lite ra tu re . The firs t is a general description, including 
c lin ica l features, o f 139 patients w ith malignant hypertension seen in 
Glasgow between 1968 and 1983. The second is of the importance o f 
d iffe ren t re tina l changes in the diagnosis o f malignant hypertension. The 
th ird  tests the possibility tha t cigarette smoking may predispose to the 
malignant phase in susceptible patients. The fourth  examines the relation 
between the oral contraceptive p ill and malignant hypertension in women o f 
childbearing age. The f i f th  evaluates the role played by abnormal 
haemostasis in the pathogenesis o f the disease. In study six the e fficacy 
and safety of slow release nifedipine and atenolol as in it ia l treatm ent fo r 
malignant hypertension are compared. The seventh and eighth analyses 
examine the changes th a t occur in renal function during treatm ent o f 
malignant hypertension, and the ninth is a study of survival.
PATIENTS & METHODS
M alignant hypertension
Seven o f the nine analyses presented in this thesis are based on a 
consecutive series o f 139 patients w ith  malignant hypertension who were 
adm itted to the Blood Pressure U nit at the Western In firm ary  in Glasgow 
between 1968 and 1983 (108 cases) or to the Renal U n it at the Royal
In firm ary  in Glasgow between 1979 and 1983 (31 cases). Seventy were men, 
mean age 45.5+11.0 (SD) years, 69 were women, mean age 42.3+15.8 years.
Selection was by case review o f patients w ith hypertension and grade 
3 or 4 retinopathy (n= 193), and a decision to include a patient based
entire ly on the appearances of the re tina l fundus was taken by an observer
(Dr AF Lever) who was unaware o f the clin ica l course or outcome. The
diagnosis of malignant hypertension was accepted i f  the attending physician 
had recorded the presence o f haemorrhages and exudates in both fundi. I f  
this information had not been given, but b ila tera l re tinal haemorrhages and 
exudates were present in fundal photographs taken at the tim e o f admission, 
the patient was also included in the study. Fundal photographs were 
available in 156 of the 193 patients.
In the remaining two studies, d iffe ren t sources o f patients w ith  
malignant hypertension were used. Study 6 was a randomised controlled 
comparison o f two drugs given ora lly  to 20 consecutive black patients w ith  
malignant hypertension in Johannesburg. Malignant hypertension occurs too 
infrequently in the United Kingdom fo r such a tr ia l to have been conducted 
in Glasgow. Study 7 was based on a series o f 7 consecutive patients 
presenting to the Royal In firm ary in Glasgow with malignant essential 
hypertension and acute renal fa ilu re . Four o f the 7 patients belonged to 
the main cohort o f 139 patients, the remaining 3 were iden tified  by review 
o f Royal In firm ary files.
Controls
Comparisons were made w ith  four control groups: w ith  patients
attending the Glasgow Blood Pressure C lin ic who had non malignant
hypertension (117), w ith  healthy volunteers, w ith  apparently healthy subjects
identified during the course o f an epidemiological survey of middle aged 
adults in Renfrew and Paisley (118-119), and w ith  data derived from  the
general population of Strathclyde (120). The particular control population
chosen fo r each analysis w ill be described in more detail w ith  the report o f 
that analysis, but i t  may be useful to discuss the two main control 
populations more fu lly  here.
Control patients from  the Glasgow Blood Pressure C lin ic  were from  a 
pool o f 3783 patients (1868 males, mean age 49 years) w ith  non malignant 
hypertension who attended the c lin ic  between 1968 and 1983 (117). These 
patients were often severely hypertensive and were referred to the c lin ic  by 
their general practitioners or by other hospital doctors. A ll had diastolic 
blood pressure of 90 or more before treatm ent; average blood pressure at 
in itia l acceptance to the c lin ic  was 183/110. Full details o f the c lin ic  and 
an analysis o f m orta lity  among patients attending the c lin ic  have been 
reported (117). The main advantage to us o f using c lin ic  patients as 
controls was that these patients were seen in the same c ity , over the same 
period and often by the same doctors, as our patients w ith  malignant 
hypertension. Also, computerisation of c lin ic  data meant tha t it  was a 
re la tive ly  simple procedure to match malignant hypertensives individually 
w ith  non-malignant controls fo r whatever baseline characteristics (fo r 
example, age, sex, year o f presentation and in itia l blood pressure) were 
considered necessary fo r a particular analysis.
For our second main control group, we used data derived from  the 
general population o f Strathclyde, since the m ajority o f our patients came 
from the West o f Scotland. To obtain these data we calculated the survival
expected o f our 139 malignant hypertensives had they been subject to the 
all-cause average m o rta lity  rates o f the Strathclyde population at the 
midpoint o f the study in 1976 (120). In this way it  was possible to compare 
survival o f patients w ith  malignant hypertension w ith th a t o f the general 
population from which they were derived. We have used this technique in 
another analysis comparing benign phase hypertensives w ith  Strathclyde 
controls (117).
STUDY Is C L IN IC A L  FEATURES OF 139 PATIENTS WITH
M A LIG N A N T HYPERTENSION
Introduction
Benign or non malignant hypertension is a common condition which 
occurs predominantly in middle aged or elderly men and women, the 
m ajority  o f whom have no underlying cause fo r the ir high blood pressure 
and do not complain of symptoms unless or until complications supervene 
(121). By contrast, malignant hypertension is rare and tends to e ffe c t a 
younger age group. Underlying causes fo r hypertension are frequently found 
and patients usually present w ith  symptoms (37,38). To determine whether 
our 139 patients w ith  malignant phase were typical o f malignant 
hypertensives generally, a descriptive study o f their c lin ica l features was 
undertaken.
Methods
C lin ica l features were recorded prospectively using a standard 
proforma in 59 consecutive patients from  1979 to 1981, and retrospective ly 
by case sheet review, collecting the same information where possible, in the 
remaining 80 patients. The quality of the retrospective data is like ly  to be 
high as complete case notes are kept and malignant hypertension is a 
special interest o f the Blood Pressure U nit.
Results
Age, sex and race
The age distribution o f patients was 20 to 66 years in men and 14 to 
67 years in women. Twenty-five (18%) were 30 years or younger at the 
tim e o f presentation w ith  malignant hypertension. No patient was older 
than 70 years. This is in marked contrast w ith  the age d istribution o f non 
malignant hypertension as determined by population surveys (fig  5) (122). 
Sex distribution was equal. 134 patients were white Caucasian; the 
remainder came from India (2), Pakistan (1), West Indies (1), Trinidad (1).
Underlying causes
The proportion of patients w ith malignant hypertension in Glasgow 
who were found to have an underlying cause fo r the ir hypertension is given 
in Table 1 where, fo r the purposes of comparison, the prevalence of 
secondary hypertension in other centres reporting the ir experience o f 
malignant phase has also been shown. In Glasgow, a possible cause fo r 
hypertension was identified in 56 (40%) patients. The commonest was 
renovascular disease in 19 (14%), confirmed by renal arteriography in 17 
cases and by autopsy in 2. Chronic glomerulonephritis was like ly  to have 
been responsible fo r hypertension in 13 cases. This diagnosis was confirmed 
in 4 cases by renal biopsy and was "probable" in the remaining 9 cases who 
gave a past h istory o f acute nephritis, nephrotic syndrome or proteinuria 
w ith hypertension and were known to have had small smooth kidneys 
preceeding the onset o f malignant phase. Ten patients had the radiological 
appearances o f chronic pyelonephritis on IV urography. Two had consumed 
large quantities o f analgesics and had radiological features suggestive of 
analgesic nephropathy. Six patients presented w ith serum creatinine greater 
than 500 umol/1 and in these a diagnosis o f primary renal disease could not 
be confirmed nor could essential hypertension be excluded. They were 
classified as having chronic renal fa ilure o f undetermined cause therefore. 
A variety of other conditions may have been responsible fo r the 
hypertension in 6 patients: unilateral small kidneys in 2 not having renal 
arteriography, hydronephrosis (1), progressive systemic sclerosis (1), 
Takayasu’s a rte ritis  (1) and noradrenaline secreting paraganglioma (1).
The remaining 83 patients were considered to have essential 
hypertension by exclusion o f other causes. E ighty-two had normal IV 
urography and 40 also had normal renal arteriography. Proteinuria greater 
than lg/24hrs was present in 10 o f these patients only. Additional 
pathological changes consistent w ith  essential hypertension were found on
renal biopsy (7 cases), fo llow ing b ila tera l nephrectomy (1 case) or at autopsy 
(5 cases). The possibility that the oral contraceptive p ill may have 
precipitated the malignant phase in 11 patients is considered in study 4. 
Sources of re fe rra l
Seventy-three patients were referred to  us from the Glasgow area: 44 
(60%) d irectly  by the ir general practitioners, 21 (29%) by the Department o f 
Ophthalmology at the Western In firm ary, Glasgow, and 8 (11%) by other 
physicians in the Western or Royal Infirm aries (3 urologists, 3 respiratory, 2 
general physicians). A fte r general practitioners, the ophthalmologists were 
the single most common source of locally referred patients in the study. 
This is like ly to re fle c t the high prevalence of visual symptoms at 
presentation. Sixty-six (47%) patients were referred from physicians working 
in other hospitals in the West o f Scotland and other parts o f the United 
Kingdom.
Duration o f hypertension
Eighty-six (62%) patients gave no past history of hypertension or had 
not had their blood pressure measured prior to the onset o f the malignant 
phase. Twenty-seven (19%) were known to be hypertensive and claimed to 
be taking the ir treatm ent at the tim e o f diagnosis. Twenty-six (19%) were 
known to be hypertensive but adm itted they did not comply w ith  therapy. 
Serial measurements of blood pressure prior to the development o f 
malignant hypertension were only rarely available. Nevertheless, the longest 
in terval between recognition of hypertension and malignant phase was 19 
years in a male patient w ith  essential hypertension, and the shortest period 
between a well-documented normal blood pressure and the malignant phase 
was 8 weeks in a 27 year old female follow ing the introduction o f the oral 
contraceptive p ill.
Blood pressure on admission
Average in itia l blood pressure was 233+27/145+18(SD) mmHg.
Diastolic blood pressure was greater than 130 mmHg in 128 (92%) of cases. 
There was, however, marked variation in in it ia l blood pressure between 
patients, from  165 to 300 mmHg systolic and 110 to 190 mmHg diastolic. 
Patients who were allegedly taking long-term antihypertensive treatm ent at 
the tim e of the ir diagnosis (n=27) had slightly lower pressure (229/143 
mmHg on average) than those whose malignant hypertension developed while 
untreated (236/147 mmHg). Another feature which may have contributed to  
the variation in blood pressure at presentation was renal fa ilure. In a 
subgroup o f 50 consecutive patients (28 male) who had not previously 
received antihypertensive treatm ent, there was a significant inverse 
correlation between in itia l mean arteria l pressure (MAP) and log ig  serum 
creatinine (r = -0.37, p<0.01 fo r maximum MAP, and r=-0.41, pO .O l fo r 
average of a ll MAP before treatment began). One explanation of th is 
finding is tha t renal fa ilu re  lowers the threshold blood pressure at which 
malignant hypertension develops.
Retinal changes, cigarette smoking, oral contraceptive p ill
A ll patients included in this analysis had b ila tera l re tina l 
haemorrhages and exudates. N inety-six had papilloedema as well. These 
fundal changes were confirmed by photography in each o f 102 cases.
Adequate smoking histories were obtained in 138 patients. 109 (79%) 
were current smokers at the tim e of presentation, 5 (4%) were ex smokers 
and 24 (17%) had never smoked.
T h irty -fo u r o f 69 women in this analysis were o f childbearing age
(15-44 years) and of these 11 (32%) were taking the oral contraceptive p ill
when malignant hypertension was diagnosed. None o f the 35 women aged 
45 or more were taking oral contraceptives or other sex hormones.
More detailed analyses o f retinal changes in malignant hypertension,
o f cigarette smoking and of the relation between the oral contraceptive p ill
and malignant hypertension in women o f childbearing age are presented in
studies 2,3 and 4. *
Symptoms at tim e o f diagnosis
Symptoms at the tim e o f presentation were recorded prospectively 
using a standard proforma in 59 consecutive patients from  1979 to 1981, 
and have been summarised in Table 2. Recent onset o f headache and visual 
upset were the commonest complaints, and also the commonest presenting
symptoms. Headache was as like ly  to be fron ta l as occ ip ita l, and had no 
tendency to occur at any particular tim e of day. Impairm ent o f vision 
preceding treatm ent was reported by 39 (66%) patients. Generally, visual 
symptoms related in degree to the severity of the re tina l changes. One 
patient however experienced sudden loss o f vision due to an associated 
central re tinal vein thrombosis, and 2 presented with visual fie ld  defects 
due to small strokes. One patient only developed visual symptoms a fte r 
treatm ent had been started: co rtica l blindness, which was transient,
developed in a 19 year old g irl whose blood pressure fe ll precipitously a fte r 
intravenous diazoxide. Gastrointestinal symptoms, including weight loss and 
breathlessness due to cardiac fa ilu re , occurred in one-third to  one-half of 
cases. Occasionally these symptoms were the presenting com plaint at the 
tim e o f diagnosis. One patient presented to the surgeons w ith  abdominal 
pain, nausea and vomiting, another consulted his general p ractitioner solely 
on account o f weight loss. Epistaxis, macroscopic haematuria, th irs t and
polyuria and fits  were much less common but provided unusual sources o f
re fe rra l. None o f the 59 patients in this analysis had chest pain due to
myocardial ischaemia. Three patients denied having any symptoms at a ll:
the ir malignant phase hypertension was discovered on routine c lin ica l 
examination.
Other c lin ica l features
Serum creatinine concentration was raised in 79% o f patients, and
moderate to severe renal impairment (serum creatinine >300 pm o l/l) was
present in 33% (Table 3). More detailed analyses o f renal function and its 
re lation to  outcome w ill be presented la te r in this thesis.
Electrocardiographic evidence of le f t ventricular hypertrophy, as 
judged by standard c rite ria  (SVlor2 + RV5or6 > 35mm or R in aVL > 
13mm) was present in 86% of our patients. Just under one-third had 
clin ica l or radiological evidence o f heart fa ilu re  at presentation. This took 
the form  of a congestive cardiac fa ilu re  in every instance, there being no 
case o f acute pulmonary oedema in our study.
Neurological complications occurred in 24/139 (17%) patients. Seven 
o f these presented w ith  a recent stroke: hemiparesis in 4, hemianopia in 2 
and an upper motor neurone 7th nerve palsy in one. Symptoms suggestive 
of transient cerebral ischaemia were present in 4 patients; these included 
transient loss of consciousness in 2, transient blindness in one and migraine­
like visual aura in one. One patient presented w ith  a lower motor neurone 
facia l palsy. Fourteen of the 24 patients w ith  neurological complications 
were considered to  have hypertensive encephalopathy: 5 o f these had grand 
mal seizures. In a ll o f these patients, neurological features were present 
before the s ta rt o f e ffec tive  antihypertensive therapy.
107/139 (77%) patients had an examination of blood film s during the 
firs t week o f the ir illness, and o f these 30 (28%) had red ce ll
fragmentation. In no instance was there c lin ica l evidence of an abnormal 
bleeding tendency. Moreover, conventional coagulation screens, where 
performed, were always normal. The results o f other haematological tests 
which were measured in 18 patients are presented in study 5.
Plasma active renin concentration was measured in 37 of the 108 
patients not on treatm ent at presentation. Elevated values (>50uU /m l) 
were found in 28 (76%). The remainder had normal plasma renin.
Increased renin was o f no value in d iffe rentia ting  the cause o f the 
hypertension in these patients, nor was i t  of any prognostic significance,
there being no tendency fo r patients w ith  higher renin values to have higher 
m orta lity .
Discussion
Although the incidence of malignant hypertension is said to be 
declining in much o f Europe and North America (1) we were nevertheless 
able to identify  139 patients in Glasgow in only 15 years, most o f whom 
were seen in one unit. We cannot say, however, whether malignant 
hypertension is particu larly  common in the West of Scotland, as d irect 
comparison of our data w ith  tha t o f other centres is not possible. Leaving 
aside the debate on diagnostic c r ite r ia  (see Study 2) factors other than the 
incidence of the disease may also have influenced the rate o f re fe rra l in 
this study. I t  is possible, fo r example, that some o f our patients were
referred because the Blood Pressure Unit has an interest in malignant 
hypertension. A lte rna tive ly , the wider ava ilab ility  o f e ffective
antihypertensive drugs may have reduced the rate of re fe rra l, as physicians 
in other centres became more confident in the use o f these drugs. Because 
the survival of loca lly-re ferred patients was sim ilar to tha t o f patients
referred from other centres (Study 9) i t  is unlikely tha t patient selection 
had an important influence on our results, and I shall consider a ll 139 
patients together in the analyses which fo llow .
The clin ica l features of our 139 patients are sim ilar to those reported 
elsewhere (37,38). Nearly a ll patients w ith malignant hypertension have
symptoms, in contrast to patients w ith  non malignant hypertension which is 
usually a symptomless condition. Headache and visual upset were the 
commonest symptoms at presentation in the Glasgow series, but were not 
always present, and the diagnosis o f malignant hypertension should be borne 
in mind when assessing patients w ith  breathlessness, weight loss, epistaxes, 
haematuria, th irs t and polyuria, and fits .
The prevalence of other c lin ica l features in the Glasgow series is
shown in Table 2. Impaired renal function was one o f the most common 
and, as w ill be seen in la ter analyses, the most serious manifestation o f 
patients w ith  this disease. Hypertensive encephalopathy, while serious, 
occurred less frequently as did heart fa ilu re  and MAH A . Increased plasma 
renin concentration, although frequent, did not appear to have any bearing 
on outcome.
Another feature distinguishing malignant from non-malignant 
hypertension in our own experience (123) and that of others (124-126) is 
that underlying causes fo r high blood pressure are frequently identified  in 
the form er but not in the la tte r. However, the proportion of patients w ith  
malignant hypertension who have an underlying cause varies from  centre to 
centre (table 1). In Glasgow, underlying causes were found in 40% o f 
patients w ith  malignant hypertension, and the commonest o f these was 
renovascular disease (4). In Melbourne, 80% o f patients had secondary 
hypertension, which was usually parenchymal in nature (5). By contrast, 
most o f the cases seen among urban blacks in Johannesburg were considered 
to be idiopathic or essential (7), an observation which has been supported by 
autopsy data from that c ity  (127). These differences are like ly  to re fle c t 
real differences in the prevalence of some diseases (e.g. analgesic 
nephropathy which is particularly common in Australia) as well as the 
enthusiasm of the diagnostic search, and the specific interests o f individual 
units. Generally speaking, when patients present w ith  malignant phase 
hypertension, a thorough search fo r an underlying cause is indicated.
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TABLE 2 SYMPTOMS AT DIAGNOSIS IN  59 PATIENTS
NO. IN WHOM
SYMPTOM
PRESENT
MAJOR SYMPTOM 
AT PRESENTATION
Headache
Visual upset
GI symptoms
Weight loss
Breathlessness
Epistaxis
Haematuria
Thirst/polyuria
Fits
None
37 (63%) 
39 (59%) 
29 (49%) 
22 (37%) 
21 (36%) 
8 
2 
3 
1 
3
17
20
3
1
9
1
2
2
1
3
The prevalence of symptoms in this table was estimated 
prospectively by questionnaire in 59 consecutive patients 
between 1979 and 1981.
TABLE 3 OTHER C LIN IC A L FEATURES
Mild renal impairment (serum creatinine 
115-300 pm o l/l or blood urea 7-15 mmol/1)
64/139 46%
Severe renal impairment (serum creatinine 
>300 umol/1 or blood urea >15 mmol/1)
46/139 33%
LVH by voltage c rite ria 118/138 86%
Cardiac fa ilu re 42/139 30%
Neurological complications 24/139 17%
Encephalopathy 14/139 10%
Microangiopathic haemolytic anaemia 30/107 28%
Secondary hyperaldosteronism 28/37 76%
The value for microangiopathic haemolytic anaemia is derived from
107 having patients having blood film s w ith in  a week o f presentation,
and the estimate fo r secondary hyperaldosteronism was based on 37
previously untreated patients in whom plasma active renin
concentration was measured. A ll other values in this table are based 
on all 139 patients in the Glasgow series.
o»
A
a.«zso
4)
>
30-,
15 -<
3
i
<oa.
3Uoo
(A♦->o
CL)
s3
<A
Hen r 20
10
frfoaen
15
15-2*1 25-3*1 35-44 *15-54 55-64 55-74
r  20
43
>
<AC49
49a.
XI
c
49
43
Co
3-O
10 -
CO
49a*
Years
FIGURE 5 Age d istribution o f malignant (O) and non malignant ( • )  
hypertension. Patients w ith  non malignant hypertension were detected 
during an occupational survey on apparently healthy men and women in the 
West o f Scotland (Greaves 1973).
STUDY 2s R E TIN A L CHANGES IN  THE DIAGNOSIS OF M ALIG NANT
HYPERTENSION
Introduction
Despite recommendations by the World Health Organisation that the 
c rite ria  fo r malignant hypertension should include hypertensive patients w ith  
b ila te ra l re tina l haemorrhages and exudates alone (8), some clinicians insist 
that papilloedema should also be present (37,38,51). To try  to resolve th is 
issue we assessed the importance o f papilloedema in severe hypertension in 
a two part study. The study has been published (128) and an outline of the 
main points is given below.
Methods
The f irs t part o f the study was a test o f observer error in which 
four observers (a consultant ophthalmologist, a consultant general physican 
and two junior hospital doctors working in the Blood Pressure Unit) were 
presented w ith  56 photographic slides o f the retinal fundus showing a 
variety o f features including haemorrhagic or exudative retinopathy, and 
were asked whether haemorrhages, exudates or papilloedema were present or 
absent. The second was an analysis o f survival, comparing prognosis a t five  
and ten years o f those patients judged to have b ila tera l haemorrhages and 
exudates alone w ith  that o f patients in whom papilloedema was present as 
well.
The re lation between presence o f papilloedema and survival was 
determined firs tly  by life  table analysis and, secondly, by Cox’s proportional 
hazards model (129) to control fo r the possible influence o f age, sex, 
smoking habit, underlying diagnosis, in it ia l serum creatinine concentration, 
and in it ia l and achieved blood pressure. We assessed the proportional 
hazards model graphically by s tra tify ing  separately fo r each co-variate and 
examining plots o f the log-log survival function.
Results
The results are shown in figs 6 & 7. Agreement between observers 
was close when haemorrhages and exudates were being assessed, but there 
was frequent disagreement on papilloedema. As expected, flo r id  
papilloedema was recognised correctly  by all observers. Disagreement was 
greatest when changes were mild. In the second part o f the study, 10 year 
survival was 48% in patients w ith  and 46% without papilloedema. The lack 
o f an association between papilloedema and survival was confirmed by 
m ultivaria te  analysis using the Cox proportional hazards model (fig  7).These 
results suggest tha t papilloedema, unless flo rid , is an unreliable physical 
sign, and that it  has no influence on survival when b ila te ra l re tina l 
haemorrhages and exudates are already present.
Discussion
A heated debate has been conducted over the years concerning the 
severity o f the fundal changes necessary to establish the diagnosis o f 
malignant hypertension. A t one extreme, the view has been expressed tha t 
"one large exudate convicts" (121). Others have argued th a t hypertension 
should not be classified as malignant unless papilloedema is present 
(37,38,51), prefering to use the term  "accelerated" hypertension to  describe 
patients w ith  re tina l haemorrhages and exudates alone (51). I t  is our view, 
that o f Pickering (121) and the WHO (8) that papilloedema need not be 
present in malignant hypertension and in support o f this, fib rino id  a rte rio la r 
necrosis, the pathological hallmark of the malignant phase, has been 
detected in hypertensive patients w ith haemorrhages and exudates alone 
(130); soft exudates and papilloedema share a sim ilar pathogenesis (131); and 
papilloedema is not constantly present even when malignant hypertension 
causes acute o liguric renal fa ilure, one of the most malignant o f a ll 
presentations of hypertension (132). To these reasons we now add the 
finding that papilloedema is o f no additional prognostic importance in
patients treated fo r hypertension who already have b ila tera l haemorrhages 
and exudates (128). Colleagues in Birmingham have conducted a s im ila r 
study and have reached sim ilar conclusions (133).
This longstanding argument w ill, i t  is hoped, now be settled. 
Agreement on the diagnosis of malignant hypertension is im portant fo r 
epidemiological purposes, and fo r the reasons outlined above the WHO 
c rite ria  have been adopted in Glasgow. In practice, hogever, one would 
never w ait fo r the fu ll syndrome to  occur, and the development o f fresh 
haemorrhages or soft exudates in a hypertensive patient, either de novo or 
when blood pressure is poorly controlled, signifies an urgent need fo r 
treatm ent.
Exudates Papilioedesa
<0<UO 30 -
Agree Disagree Agree Disagree Agree Disagree
FIGURE 6 The four observers agreed that haemorrhages were present or 
absent in 52 o f 56 slides, and disagreed in 4 (7%) cases. A sim ilar 
consensus was obtained fo r exudates, w ith disagreement in 3 (5%) cases. 
Opinion on papilloedema, however, was divided, the observers agreeing in 
only 34 of the 56 cases.
Bilateral Haemorrhages 
.exudates and papilloedemaas>
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14 with papilloedema 
5 without papilloedema
8 1080 2
Years
FIGURE 7 Relation between papilloedema and survival in 139 hypertensive 
patients w ith b ila tera l retinal "~Raemorrhages and exudates a fte r contro lling  
fo r age, sex, smoking habit, underlying diagnosis, in itia l serum creatinine 
concentration, and in itia l and achieved blood pressures by m u ltiva ria te  
analysis. Numbers o f patients observed at beginning o f each tim e in te rva l 
are given. A fte r 8 years there were no deaths among 6 remaining patients 
w ithout papilloedema. Failure o f papilloedema to  influence prognosis was 
confirmed by likelihood ratio  test (chi-squared = 0.89, ld f ,  p= 0.34).
STUDY 3: C IG ARETTE SMOKING M A Y PREDISPOSE TO M A LIG NAN T
HYPERTENSION
Introduction
Our study on the association between cigarette  smoking and malignant 
hypertension was prompted by the observation tha t diabetics who smoked 
were more like ly  to develop pro life ra tive  and haemorrhagic retinopathy than 
diabetics who did not (134). Malignant hypertension is characterised by 
another form  o f ischaemic retinopathy, but as fa r as we were aware, the 
smoking habits o f patients w ith the condition had not been reported. Our 
findings, which were published in 1979 (18), are summarised below.
Methods
The prevalence o f cigarette smoking in malignant hypertension was
determined by case review of 82 consecutive patients adm itted to the Blood 
Pressure U nit w ith  this diagnosis between 1968 and 1978, and comparisons 
were made w ith  3 control groups. The f irs t  control consisted o f 82 patients 
w ith non-malignant hypertension who had been admitted to  our wards during
the same period, and who were matched individually fo r age and sex w ith
the index group. The second control comprised 164 patients w ith non-
malignant hypertension obtained from the files o f the Glasgow Blood 
Pressure C lin ic. Two control subjects were matched individually fo r age 
and sex w ith  each patient in the malignant phase. For our th ird  control we 
used 82 subjects in the general population who had been screened during the 
course o f an epidemiological survey o f 13000 apparently healthy middle-aged 
men and women in Renfrew and Paisley between 1972 and 1976. Each 
patient w ith  malignant hypertension was matched by computer w ith  a person 
of the same age (where possible) and sex from  Renfrew and Paisley.
The proportion o f smokers among patients and controls was compared 
using the chi-squared test and Yates’s continu ity correction. The re la tive  
risk o f smokers having the malignant phase was determined by the odds
ra tio .
Results
Sixty-seven (82%) of the patients w ith  malignant hypertension were 
smokers compared w ith  41 (50%) non malignant hypertensives from  the 
ward, 71 (43%) non malignant hypertensives from  the c lin ic  and 43 (52%) of 
the general population in Renfrew and Paisley. D ifferences between the 
malignant phase and contro l groups were significant fo r both sexes 
separately and together, fo r all forms of smoking combined and fo r 
cigarette smoking alone (Table 4). There were no s ign ificant differences 
between the control groups. Hypertensive patients who smoked were on 
average 4.3-6.9 times more like ly to  be in the malignant phase than 
hypertensive patients who did not smoke (Table 4).
Discussion
The main finding o f our study was a large excess o f smokers among 
patients w ith malignant hypertension. The excess is a feature of the 
malignant phase, not o f hypertension generally. Colleagues in Birmingham 
came to the same conclusion (19) and sim ilar findings have subsequetly been 
reported from  other centres (20,21). An interesting exception to  this trend 
is the study from  Johannesburg (7) in which cigarette smoking was not a 
feature of urban blacks w ith  the malignant phase in whom, as described 
previously, the disease appears to be particu la rly  common.
Clearly then smoking may predispose to malignant phase hypertension 
but i t  is not the only precip itant. Smoking could act as a trigger in 
susceptible subjects, and i t  may exert its e ffec t by promoting intravascular 
coagulation (135). A lte rna tive ly  smoking may be a marker fo r some other 
variable which is itse lf a cause o f malignant hypertension. Hypertensives 
w ith negative attitudes to health may be more like ly to default from  
c lin ica l attendance and less like ly  to comply w ith therapy, and may thus be 
predisposed to develop the malignant phase (135a). Such patients may also
more like ly to smoke. This is an area which deserves fu rthe r study.
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STUDY 4: RELATIO N BETWEEN THE ORAL C O NTRACEPTIVE P ILL  
AND M A LIG N A N T H YPERTENSIO N,
Introduction
Although malignant hypertension is a well recognised com plication o f 
the oral contraceptive p ill (22-29), most reports of its occurrence have been 
lim ited  to case studies o f selected patients only, and as such the c lin ica l 
features and outcome o f the malignant phase in p ill users had never been 
fu lly  defined. This was the main purpose of our study (30).
Methods
The case records of the 69 women in the main analysis (Study 1)
were reviewed to determine whether they had been taking the oral
contraceptive p ill or other sex hormones at the tim e o f diagnosis o f the ir 
malignant hypertension. I f  this information had not been recorded in the 
notes, the patients or the ir general practitioners were contacted. In these 
ways a drug history was established fo r a ll but 2 patients, who were
considered to be non users. Following in itia l assessment, blood pressure,
drug therapy, renal function and other events were monitored to 1.4.84. I f
death occurred in the United Kingdom, record linkage w ith  the Registrar 
General ensured that the data and certified  cause of death was no tified  in 
each case.
The differences in the c lin ica l features of p ill users and non users
w ith  malignant hypertension were assessed by t-tests. Survival in the tw o
groups was by life  table analysis, and comparison o f the survival curves by
the log rank test.
Results
Relation o f malignant hypertension to p ill, and type o f p ill
Th irty -fou r o f the 69 women were o f childbearing age (a rb itra rily  15 
to 44 years) and of these 11 (32%) were taking oral contraceptives at the 
tim e o f presentation w ith malignant hypertension. None o f the women aged
45 or more was taking oral contraceptives or other sex hormones. The 
mean age o f the p ill users was 31 years. Blood pressure was known to be 
normal immediately before starting the p ill in 6 women and w ith in  3 years 
of starting the p ill in a fu rthe r 3. In the remaining 2 women, 'normal blood 
pressure had been recorded 13 and 21 years before the p ill, but more recent 
measurements were not available. Four women developed malignant 
hypertension w ith in  4 months of starting the p ill, while in the others 
malignant hypertension did not develop fo r 14 months to 8 years. The 
commonest preparations were those containing 50 ug or oestrogen or more 
(8 cases). Two patients developed malignant hypertension while taking 30 
ug of oestrogen, and 1 presented w ith in  8 weeks of starting a 20 ug 
oestrogen p ill. Blood pressure in this patient was 110/70 mmHg 
immediately before treatm ent began. Apart from  the oestrogen component,
preparations taken included 4 d iffe rent progestagens (Norethisterone,
Levonorgestrel, Lynoestrenol, Ethynodiol), two of which (Norethisterone, 
Levonorgestrel) were present in d iffe rent doses.
C lin ical features and prognosis
The c lin ica l features and prognosis o f the 11 women who developed 
malignant hypertension while taking the oral contraceptive p ill, were 
compared w ith  those o f the 23 women who were also o f childbearing age 
but who were not taking the p ill (Table 5). Other details in four o f the
p ill users have been reported elsewhere (28). Age, in itia l blood pressure and
smoking habits were sim ilar in the two groups. 73% o f p ill users, and 74% 
of non users smoked cigarettes, a higher than usual proportion than in the 
Scottish population and in women attending the Glasgow Blood Pressure 
C lin ic w ith  non malignant hypertension (18). P ill users had less underlying 
renal disease and less renal fa ilure than non users. The level o f blood 
pressure achieved during treatm ent was sim ila r in the two groups. No p ill 
user became normotensive following w ithdrawal o f the p ill, but d iastolic
blood pressures consistently less than 90 mmHg were recorded during 
follow-up in 3 patients while taking one antihypertensive drug only. By 
contrast a ll 23 non users required two or more drugs to control blood 
pressure. Ten year survival was 90% among p ill users but only 50% among 
non users (Table 5). This was related at least in part to the higher 
incidence o f renal fa ilu re  in non users, 8 o f whom eventually developed end 
stage renal fa ilu re  requiring dialysis.
Discussion
There are several mechanisms by which the contraceptive p ill could 
cause malignant hypertension. Malignant hypertension may develop as a 
consequence o f the known pressor e ffects o f oestrogens and/or progestagens. 
Thus, the rapid rise in blood pressure which occurs in malignant 
hypertension may be an extreme example o f the varied increase in pressure 
noted when most women are given the p ill (49). A lte rna tive ly , malignant 
hypertension may be a consequence of some other property o f oral 
contraceptives. I t  is known that oral contraceptives activate the 
coagulation system (136) and tha t in-situ thrombosis causes other 
cardiovascular complications o f the p ill. As w ill be discussed in Study 5, 
abnormalities o f blood coagulation are well recognised in malignant 
hypertension not associated w ith  oral contraceptives. I t  is possible 
therefore that in-situ thrombosis involving either the main (137) or the 
intrarenal (138) arteries could contribute to the pathogenesis o f malignant 
hypertension in p ill users.
C lin ica lly , the most s trik ing  difference to emerge between the p ill 
users and controls in the study, was tha t p ill users had less underlying renal 
disease and less renal fa ilu re  than non users. By contrast, 6 o f 9 previously 
recorded patients in the lite ra tu re  had appreciable renal im pairm ent 
(23,25,26). Whether our findings re fle c t more accurately the natural h istory 
o f p ill associated malignant hypertension, or merely the fa c t tha t women
who are known to be hypertensive or unwell fo r other reasons are less 
like ly  to  be given the p ill, is not clear. C erta in ly, selection bias may have 
determined the high prevalence of renal impairment among the patients 
described in previous reports, many o f whom were adm itted to  renal units.
As the degree o f renal impairment at presentation is the single most 
im portant predictor o f outcome in patients w ith  malignant hypertension (4) 
i t  is perhaps not surprising that most of our patients did w ell. Although a 
return o f blood pressure to normal a fte r w ithdrawal o f the p ill is the 
exception rather than the rule (occurring in 2 o f 9 patients in previous 
reports and in none of our 11 patients), blood pressure was w ell controlled 
in most o f our cases and 10-year survival was 90%. This result compares 
favourably w ith  the 10-year survival o f only 50% among the women w ith  
malignant hypertension who did not take the p ill. The higher prevalence o f 
renal disease and renal impairment among the non users seems the like ly  
explanation.
TA
BL
E 
5 
CO
MP
AR
ISO
N 
OF 
WO
ME
N 
TA
KIN
G 
PIL
L 
WI
TH
 
TH
OS
E 
NO
T 
TA
KIN
G 
PI
LL
0}
a)
Eo .= II
>  J* C>  CD
O
CM
On <t 1^  t/\
VO
00
K \
o  m r^FVHH
CM VO H i—I r-H
00
CM
<rKNKV
Ov
OV
KV 00
CM Ov 
VO < t
O
CM
ITV
•H
CO
C Q.(D -—'
E
| £ £cnw
.E15CO
KV
^  ^  Ov00 K\ KS <3-—- <r <-h
rH  Ov
H  00  IA  
CM
CM
r*v
CM
VO
CM
VO
CM
CM
00
CD
VO
VOm
LTV iT\
Ov Ov 
CO 00
"O
cCO
0
c_3
co
m0c_
O .
*D
OO
.. Q
3  <2
Cmffl c0 s 
>%
0CTl
<
cn
I
E
E
0© ® 6- ©^ ©
CD ®
CD = 0  0 ®
Cm
(0
_  C 012 © 2 O r_ 0O 0
3  p ®c -D
0cn
c
9m4
0
"D
0
C
c_.
0
4 -1
0■O
«  c  .2  3
4-1
Jl ^  03 *£5 »8
£ §3CL*2 ‘
0
© o C
>s —H ©
cl cn c-
u © 
C- H -
±! o-=
-- "E 3
-C ^© v  c  ® -1  C)
§ . c t u u uo
a o o
*c ‘c 3  o o oL L Lj r  _c x:
o 
E 2 ■> ✓<r0 ao
1 $  *n *h
oZ 0l z
0
0
Cma
0  E 
E Eo ©
£ •a — o 0
E2
2 .£ 
-C
o Q  
0  cn 
0
a. g 
0 z
CD
4 ->
0
0 
Cm 2 
09 
CD
©  'OS; -cm cn^r° - i5
-D E " 1 
S E °
3 —  / - s  -e'en ®
^  4 -1  JyC CD t- f
D 0 •V-i’ Cm 0  ©  0 0 cn -q —• -  -0 S> >*> ^  c t* •- Offl o >  IA H  
0
Z  cn
TJ
C
0
3
4-13
J0
0JC
cn
£so
E
03
aTcn
0
Q cr
ea
tin
in
e 
co
nc
en
tra
tio
n 
no
t 
si
gn
ifi
ca
nt
ly
 
by 
un
pa
ire
d 
t 
te
st
.
STUDY 5: ABNORMAL HAEMOSTASIS AND M A LIG N A N T
HYPERTENSION
Introduction
The deposition of fib rin  w ith in blood vessels o f the kidneys of 
patients w ith  malignant hypertension suggests that disordered coagulation 
may be a feature o f the disease. In a previous study from  Glasgow, Gavras 
and colleagues (16) found abnormalities o f haemostasis suggestive o f low 
grade coagulopathy in a group o f patients w ith  malignant hypertension, but 
not in non-malignant controls. As a result of these findings, i t  was 
postulated tha t abnormal haemostasis was a necessary step in the transition 
from the benign to malignant phase. More recently i t  has been shown tha t 
patients w ith  renal disease who do not have malignant hypertension may 
also have high levels of fibrinogen, fac to r VIIIc, fib rin o ly tic  inhibitors and 
FDP and decreased platelet counts. To examine the relation between 
malignant hypertension, renal fa ilure and haemostasis in more deta il, a 
fu rthe r study was undertaken. A report o f our findings has been published 
(17).
Methods
Haemostatic and haemorheological variables were measured in three 
groups of subjects: Group 1 comprised 18 consecutive patients w ith
malignant hypertension admitted fo r investigation in 1979-1980. Group 2 
consisted o f 18 healthy volunteers, and Group 3 o f 18 non-malignant 
hypertensives attending hypertension and renal clin ics. Groups 2 and 3 
were matched fo r age, sex and smoking habit w ith  patients in Group 1, and 
Group 3 patients were selected in addition to have comparable levels o f 
blood pressure and serum creatinine as w ell as sim ilar renal pathology 
(Table 6).
Blood was taken w ith minimal occlusion from  a forearm vein, and 
anticoagulated w ith  trisodium c itra te  (0.129 mol/1, 9:1 v:v). P la te le t-poor
plasma was obtained by centrifugation fo r the follow ing coagulation tests - 
fibrinogen (Dade Fibrometer and Standards), facto r VIEIc by a one-stage 
assay (139), antithrombin III a c tiv ity  (w ith  heparin) and fast antiplasmin 
ac tiv ity  on chromogenic substrates (Chromozym, Boehringer), plasminogen by 
a caseinolytic assay (140), and alpha2-macroglobulin antigen by radial 
immunodiffusion (Behringwerke antiserum). Plasma beta-thromboglobulin 
(BTG) was measured by radioimmunoassay (Radiochemical Centre, 
Amersham). Serum FDP was measured by tanned red cell haemagglutination 
inhibition immunoassay (Wellcome FDP k it). Serum creatinine was measured 
by Technicon Autoanalyser. Blood was anticoagulated w ith  dry edetic acid 
(EDTA, 0.004 mol/1) fo r measurement o f blood viscosity at a high shear ra te  
(94 s” l )  and at a low shear ra te  (0.94 s“ ^) in a Contraves LS 30 ro ta tiona l 
viscometer, 37°C; haematocrit by Hawksley m icrocentrifuge (13,000 g fo r 5 
mins); p la te le t count (Coulter Thrombocounter); and plasma viscosity (BS M3 
capilliary viscometer obtained from  Poulten, Seiz and Lee, Wickford, Essex 
UK; 37°C). Blood viscosity was corrected to a standard haematocrit o f 
0.43, using regression equations fo r each shear rate obtained from  200 
samples o f widely varying haem atocrit. Red ce ll deform ability was assessed 
as the f ilte ra b ility  of red cells in plasma, haem atocrit 0.45, through special 
quality Nuclepore polycarbonate filte rs  (pore diameter 5 um), correcting fo r 
plasma viscosity as described by Buchan (141). Blood film s were reviewed 
by a consultant haematologist unaware o f the c lin ica l diagnosis fo r red ce ll 
fragmentation (evidence o f MAHA). D ifferences in means were analysed by 
Wilcoxon's rank sum test, and correlations determined by the method o f 
least squares.
Results
Compared to healthy controls (Group 2), both groups o f hypertensives 
had significantly increased plasma viscosity, blood viscosity, fibrinogen, 
facto r VIIIc and beta-thromboglobulin, and s ign ificantly  decreased
haematocrit, antithrombin III and p la te le t count. Fast antiplasmin and 
alpha2“macro9iobuiin were elevated in Group 1, but not in Group 3. 
Plasminogen was decreased in Group 3. Both groups o f hypertensives had a 
non significant increase in serum FDP. Red cell de form ab ility  was the 
same in a ll three groups.
When the two groups o f hypertensives were compared w ith  each 
other, patients w ith  malignant hypertension (Group 1) had higher levels o f 
fibrinogen (p<0.05), alpha2-macroglobulin (p<0.01) and plasminogen (p<0.05). 
Fast antiplasmin was also raised in Group 1 but not s ign ifican tly  so.
Several variables were s ign ificantly  correlated (r=0.3-0.5) w ith  serum 
creatinine. Plasma viscosity, fibrinogen, facto r VIIIc, FDP and beta- 
thromboglobulin showed positive correlations w ith  creatinine; while 
haematocrit, antithrombin III and p latelet count showed negative 
correlations.
Three patients in Group 1 had evidence o f red ce ll fragm entation on 
blood film s; the ir results were not obviously d iffe ren t from  those of the 
other 15 patients.
Discussion
This study confirms the findings o f Gavras et al (16) tha t patients 
w ith malignant hypertension (Group 1) have several abnormalities of 
haemostasis: decreased mean p la te le t count, and increased mean levels o f 
fibrinogen, factor VIIIc and FDP (although the increase in FDP was not 
s ta tis tica lly  significant). Patients w ith  malignant hypertension also had a 
decreased mean level o f antithrombin HI, fo r which Gavras et al had 
insuffic ient samples to  analyse (16), and elevated levels o f beta- 
thromboglobulin. These haemostatic abnormalities are consistent w ith  
activation o f haemostasis. Furthermore, we have shown increased levels o f 
plasma viscosity and blood viscosity (corrected for haem atocrit), which 
might contribute to disordered tissue perfusion in malignant hypertension.
Red cell deform ability was normal a fte r correction fo r the influence o f 
plasma viscosity, and was not d iffe ren t in the patients w ith  evidence of 
MAHA.
However, s im ilar abnormalities were also found in patients who did 
not have the re tina l changes o f malignant hypertension, but who were 
carefully matched fo r age, sex, smoking habit, renal pathology and levels o f 
blood pressure and serum creatinine (Group 3). Most variables correlated 
w ith  serum creatinine, and i t  is possible therefore that low grade 
coagulopathy may be a consequence o f renal fa ilu re , rather than a necessary 
step in the pathogenesis of malignant hypertension. An a lte rnative  
explanation is that both hypotheses are true, namely tha t malignant 
hypertension causes renal damage which activates haemostasis, which in turn 
promotes fu rther renal damage. In this context it  should be noted th a t 
there is morphological evidence o f intravascular coagulation in several renal 
disorders other than malignant hypertension (13).
A weakness o f both the present study and the orig inal study (16) as a 
test of the coagulation hypothesis is that the blood pressure o f patients 
w ith malignant hypertension was lower at the tim e o f blood sampling than 
at presentation. Malignant hypertension requires urgent treatm ent and i t  
was not possible to obtain blood prior to starting treatm ent. The reported 
haemostatic changes may have been d iffe ren t to those present in it ia lly . 
However, a ll patients s t il l had b ila te ra l haemorrhages and exudates at the 
tim e of sampling, and in 11 patients repeat sampling one week la te r showed 
l i t t le  change in results. I t  seems unlikely therefore tha t these variables 
a lte r rapidly during the f irs t weeks a fte r presentation.
TABLE 6 C LIN ICAL DETAILS OF PATIENTS (MEAN+SEM)
GROUP 1 GROUP 2 GROUP 3
Malignant Healthy Non-malignant
hypertension controls hypertension
j
No 18 18 18
Male sex 13 13 13
Smokers 11 11 11
Age (years) 38+3 40+3 40+3
Blood pressure (mmHg)
- systolic 165+6 121+4 173+9
- diastolic 102+4 7 5+3 99+5
Creatinine (umol/1) 435+83 79+5 399+69
Renal pathology
- glomerulonephritis 5 0 5
- other renal disease 5 0 5
- no renal disease 8 18 8
Micro-angiopathic
haemolytic anaemia 3 0 0
TABLE 7 RESULTS OF BLO O D  STUDIES IN  P A T IE N T  GROUPS
(M EAN  + SEM)
GROUP 1 GROUP 2 GROUP 3
Malignant
hypertension
Healthy
controls
Non-malignan
hypertension
Fibrinogen (g/L) 4 .87+0 .36** 2.90+0.21 3 .89+0.32**
Factor VIIIc (u /m l) 2 .32+0.32** 1.31+0.08 2.06+0.26**
Antithrom bin III (u /m l) 15 .7+0 .6** 18.8+0.7 14 .5+0 .9**
Fast antiplasmin (U/m l) 3 .9 + 0 .5 ** 2.4+0.3 3.0+0.4
Alpha2-macrogIobuIin 
(% normal pool)
131+8** 104+5 92+4
Plasminogen (casein U/m l) 2.8+0.2 2.7+0.1 2 .1+0 .2*
F ibrin degradation 
products (ug/m l)
7.8+1.6 4.5+0.7 7.3+1.7
Beta thromboglobulin 
(ng/ml)
85+8** 42+3 69+5**
P la te le t count (x 10^/L) 233+18* 282+18 233+11*
Plasma viscosity (mPa-s) 1 .36+0.03** 1.24+0.02 1 .35+0 .03**
Haematocrit 0.359+0.022** 0.445+0.006 0.370+0.018*
Blood viscosity (mPa-s) 
High shear 
Low shear
5 .91+0.25**
21 .4+0 .7**
4.92+0.14
18.5+0.6
5 .75+0 .14**
20 .4+0 .06**
Red cell deform ability 
(m i/m inute)
0.44+0.03 0.44+0.01 0.44+0.01
Asterisks indicate signficiant differences from Group 2 (healthy controls). 
*p<0.05, **p<0.001
STUDY 6s SLOW RELEASE N IFED IP IN E  AND ATENOLOL AS IN IT IA L
TREA TM EN T FOR M A LIG N A N T HYPERTENSION
Introduction
Since precipitous fa ils  in pressure in patients w ith  severe hypertension 
may cause ischaemic damage to brain (77,78), eye (79-82), kidney (83) and 
spinal cord (84) i t  has been recommended tha t parenteral therapy be avoided 
where possible (2) and tha t in itia l treatm ent should be w ith  one or two 
drugs given ora lly instead. In this study the e fficacy and safety o f slow 
release nifedipine and atenolol were compared in 20 consecutive black 
patients w ith  malignant hypertension. The study was conducted at the Non 
European Hospital in Johannesburg between June 1983 and February 1984. 
Malignant hypertension occurs commonly among urban blacks (7) and is a 
frequent cause fo r admission to the Non European Hospital.
Methods
Twenty consecutive black patients w ith untreated malignant 
hypertension whose diastolic pressure remained greater than 120 mmHg a fte r 
3 hours bed rest, were randomised to  receive e ither slow release nifedipine 
40 mg at 0 and 12 h, or atenolol 100 mg at 0 h only. None had received 
antihypertensive drugs during the 48 h before admission to hospital.
Patients remained supine throughout the study. Blood pressure was 
measured at 15 minute intervals from  -3 to  24 h by a semi automatic 
recorder (Omega 1000) the accuracy and reproducib ility o f which were 
checked against a standard mercury sphygmomanometer at m onthly intervals. 
R esults
Average blood pressure in the 10 patients given nifedipine was 
233/142 mmHg immediately prior to the f irs t  dose (baseline pressure), 
185/112 mmHg at Ih , and reached its  lowest value o f 166/100 mmHg a fte r 
5 h (fig  8). Thereafter blood pressure rose gradually to  191/119 mmHg at 
12 h. A second trough level, 157/94 mmHg was recorded 4 h a fte r the
second dose. Mean blood pressure at the end o f the study in the nifedipine 
group was 188/114 mmHg.
Baseline blood pressure in the atenolol group was 226/141 mmHg.
One hour a fte r atenolol, mean blood pressure had fa llen to  210/132 mmHg.
Blood pressure continued to  fa ll,  reaching its lowest value o f 162/100 mmHg 
at 16 h, before rising gradually to a mean o f 173/112 mmHg at 24 h.
Whereas the rate o f reduction o f blood pressure a fte r nifedipine was 
greater than a fte r atenolol ( A  BP at lh  nifedipine = 52/31 mmHg, A  BP 
at lh  atenolol = 22/11 mmHg, p<0.001 fo r systolic and diastolic pressure), 
the duration of action of a single dose of atenolol was longer than that o f 
nifedipine and the extent o f the fa ll was the same ( ^ B P  5h a fte r f irs t 
dose nifedipine = 67/41 mmHg, A  BP 16h a fte r atenolol = 64/40 mmHg).
No patient developed focal neurological signs at any tim e during
admission to hospital, nor was heart fa ilu re  precipitated by e ither form  o f 
treatm ent. The lowest MAP recorded in any patient was 53% o f baseline 
MAP (figure 9 ). This occurred 3.5 h a fte r nifedipine in one patient, 16h 
a fte r atenolol in another. The most rapid decline in MAP was to 67% o f 
the baseline value w ith in  30 min of the f irs t dose of n ifedipine. Since
acute reduction of pressure to a value not less than 45% o f baseline is 
unlikely to cause symptoms o f cerebral ischaemia (142), both drugs appear 
to have been safe in this tr ia l.
Discussion
Nifedipine has been shown previously to be highly e ffec tive  as in it ia l 
therapy in blacks w ith  malignant hypertension (7) and in whites w ith  severe, 
including malignant hypertension (86,143) although the very rapid onset o f 
action of the capsule form  has led to concern regarding its safety. We 
were interested, therefore, to  test the slow release preparation o f the drug. 
Transient re tinal ischaemia has been reported a fte r 20 mg capsule nifedipine
(144) but this complication was considered to be due to  a steal phenomenom
and was not associated w ith a precipitous fa il in pressure; we know o f no 
other neurological complications fo llow ing the use o f nifedipine alone. 
Indeed, in one small study cerebral blood flow  increased in 4 of 5 patients 
w ith  severe hypertension who were given 10-20 mg capsule nifedipine ora lly  
(86) suggesting tha t nifedipine, like other drugs in this class e.g. nimodopine
(145) has cerebral vasodilator properties. Our results confirm  the more 
gradual onset o f the slow release preparation and that i t  possesses the 
advantage o f a more prolonged action.
A tenolo l is also e ffective  when given as in itia l therapy in whites w ith  
malignant hypertension (85) but its use has not been described in blacks 
w ith  this disease, despite a higher prevalence of malignant hypertension 
among black people (7). This may re fle c t a view that beta adrenoceptor 
blockers are less e ffective  in blacks than whites (146). While this is 
probably true when beta adrenoceptor blockers are used as f irs t  line therapy 
in blacks w ith  non malignant hypertension (147) blacks w ith  malignant 
hypertension may respond to these drugs since high renin values are common 
in the malignant phase in both races (130,148). Hence or otherwise, 
atenolol was found to be as e ffective  overall as nifedipine, the effects o f a 
single oral dose o f 100 mg persisting fo r up to 24 h. Of equal interest, we 
believe, was the more gradual reduction of blood pressure achieved by 
atenolol in the study. Review of the lite ra tu re  indicates tha t there have 
been no reports of neurological complications in malignant hypertension 
fo llow ing the use o f atenolol alone.
In summary, both slow release nifedipine and atenolol lowered blood 
pressure in black patients w ith malignant hypertension. The maximum 
reduction in blood pressure was the same in the two groups although the 
rate o f fa ll o f pressure was greater fo r nifedipine and the duration o f 
action longer fo r atenolol. There were no precipitous fa lls  in pressure. 
These results support recommendations that most patients w ith  malignant
hypertension can be managed w ithout recourse to parenteral therapy.
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FIGURE 8 Blood pressure (mean+SD) and heart rate a fte r slow release 
nifedipine (®) and atenolol (O). Each value represents the mean o f the ha lf 
hourly readings in each treatm ent period fo r each patient. The fa ll in 
systolic and diastolic pressure, and the change in heart rate, was s ign ificant 
(p<0.01) at a ll times a fte r lh  in both treatm ent groups.
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FIGURE 9 Histogram showing changes in mean arteria l pressure a fte r slow 
release nifedipine and atenolol as a percentage o f baseline mean a rte ria l 
pressure. The estimates o f the lower lim it o f autoregulation (75% o f in itia l 
MAP) and the lowest tolerated pressure (45% of in itia l MAP) are from  
Strandgaard (1976) and suggest tha t no patient had a dangerous fa ll o f 
pressure in this study.
STUDY 7: M A LIG N A N T HYPERTENSIO N PRESENTING W ITH AC UTE
R E N A L F A ILU R E
In tro d u c tio n
Recovery o f renal function in malignant hypertension complicated by 
severe renal insufficiency is uncommon particu larly in the presence o f
underlying renal disease (109,111). A rare but im portant exception is the 
patient w ith  malignant hypertension who presents w ith  acute renal fa ilu re  
(96). The purposes o f this analysis were two fold. F irs t, to review the 
clin ica l and histological features o f 7 patients presenting w ith  malignant 
hypertension and acute renal fa ilu re  between 1977 and 1981 a ll o f whom
received peritoneal dialysis and hypotensive therapy. S ignificant recovery o f 
renal function occurred in 5 patients and the progress o f each has since 
been followed fo r up to 5 years. Second, to identify the reason fo r such a 
high recovery rate in this group o f patients. A report o f this analysis was 
published in 1984.
Methods
The case records o f 7 patients who presented to the Renal Unit o f 
the Royal In firm ary in Glasgow w ith  malignant essential hypertension and 
acute renal fa ilu re  between 1977 and 1981 were reviewed. The diagnosis o f 
malignant essential hypertension was based on WHO c rite ria  (1978) and was 
confirmed by renal biopsy in each case. The progress o f the 7 patients
over a period ranging from  15 to  62 months (mean 42 months) was
documented, and the c lin ica l and histological features o f the five  in whom 
renal function recovered were compared w ith  the two in whom i t  did not. 
R esu lts
Details o f these patients histories and investigations are shown in 
Table 8. A ll were white and all smoked. Their age range (20-67 years) 
was typ ica l o f malignant hypertension. Only one was known to have been 
hypertensive (fo r 6 weeks) before presentation. A ll satisfied the c rite r ia  fo r
the malignant phase having severe hypertension w ith b ila tera l re tina l 
haemorrhages and exudates: 3 had papilloedema was w ell. MAHA was 
present in the 6 patients in whom it  was sought. A ll 7 patients had acute 
renal fa ilu re  requiring immediate dialysis, and 4 were oligo-anuric. Six 
patients had other complications o f malignant hypertension including 
congestive cardiac fa ilu re  and hypertensive encephalopathy.
The managment o f these patients consisted of control o f blood 
pressure and peritoneal dialysis. Four of the 7 were resistant to a 
combination of beta blockers, hydralazine, methyldopa and frusemide and 
required m inoxidil before the ir diastolic pressure fe ll consistently below 90 
mmHg. In 5 patients renal function recovered su ffic ien tly  to stop 
peritoneal dialysis a fte r 10-44 days. Serum creatinine fe ll gradually fo r up 
to 12 months and thereafter remained stable at a mean o f 248 um o l/I 
(range 123-330 u mol/1) a fte r an average 42 months fo llow  up (15-62 
months). Two patients did not recover renal function despite adequate 
control o f blood pressure. One patient (patient 3) had only 16 days dialysis, 
which we would now consider an inadequate tr ia l. However, his biopsy 
showed more extensive changes than any other, and he was un fit fo r regular 
dialysis. He died o f renal fa ilu re . The other patient (patient 6) remains 
well on CAPD 28 months a fte r presentation w ith  no sign o f renal recovery.
Examination of the biopsies of these 7 patients showed tha t a ll had 
significant vascular damage w ith  marked subintimal cellu lar p ro life ra tion , 
oedema and fibrosis. Fibrinoid arterio lar necrosis and intra lum inal fib r in  
thrombi were present in patient 2 only; this patient’s illness may have been 
triggered by the oral contraceptive p ill. Varying degrees o f tubular 
d ila ta tion, in te rs titia l fibrosis and inflam m atory in filtra te  were seen: tubular 
regeneration was present in 4 out of 5 biopsies of patients who recovered 
but in neither of the two who did not. By contrast the glomeruli were 
re la tive ly normal showing ischaemic changes only, as judged by tu f t
collapse, wrinkling o f the basement membrane and focal necrosis.
Examination o f the biopsies by electron microscopy and 
immunofluorescence excluded prim ary glomerular pathology in all but one 
patient. This was again patient 2 whose biopsy showed weak linear
deposition of IgG. There was no clin ical evidence of pulmonary 
abnormality. The ligh t microscopic and u ltrastructura l changes were in 
keeping w ith microvascular disease and her subsequent history was most 
unlike anti-GBM nephritis. For these reasons we have included her in the 
study.
Discussion
Malignant hypertension was f irs t  recognised as a cause o f acute renal 
fa ilu re  in 1931 (149) but i t  was not un til 1971 that the f irs t report o f short 
term  recovery was published (96). That report described transient
improvement in renal function in 3 out o f 10 patients but, w ith in  two years,
nine o f the patients had died and the tenth was on dialysis. The most
strik ing feature of the series was fa ilu re  to achieve more than temporary 
control of blood pressure. With the introduction o f more potent 
antihypertensive drugs and the wider availability  of dialysis, several reports 
have since confirmed the potential fo r significant and sustained improvement 
o f renal function in these patients (97-108).
Although uncommon, the diagnosis should be considered in a ll patients 
w ith  malignant hypertension and renal fa ilure, especially i f  o liguric. 
Characteristic features include normal sized kidneys as seen on high dose 
urography, and marked vascular changes w ith well preserved glomeruli on 
renal biopsy (99). Good control o f blood pressure is essential i f  
improvement of renal function is to fo llow . Peritoneal dialysis allows a 
smoother control o f blood pressure than haemodialysis and may be 
preferable therefore when acute renal fa ilure complicates malignant 
hypertension (105). Dialysis should be continued for a period o f several
months before concluding that recovery o f renal function w ill not occur (99- 
102,104).
On retrospective review of a ll available c lin ica l and histological 
m ateria l, the only feature which appeared to be of value in predicting 
recovery o f renal function was the presence o f tubular regeneration, the 
hallmark of acute tubular necrosis, on renal biopsy. This was found in 4 
out o f 5 patients who recovered, but was absent in the 2 who did not. On 
the basis o f this observation we propose the follow ing model fo r the 
development o f acute renal fa ilu re  in malignant hypertension. F irs t, in tim a l 
pro life ra tion  and oedema leads to narrowing o f the lumen of the small renal 
arteries. This in turn causes a reduction in glomerular blood flow  and 
filtra tio n  rate. I f  this occurs very quickly, acute tubular necrosis and 
oliguria result. Such a lesion should be reversible. If , on the other hand, 
the reduction in glomerular blood flow  occurs more slowly, then unidentified 
adaptive changes may prevent the development o f acute tubular necrosis, 
thus prolonging the tim e before the patient presents and increasing renal 
parenchymal destruction. Such patients would be less like ly  to recover 
renal function.
Other observations support this hypothesis. F irs t, K err (103) has 
stated that in the absence of "reversible" factors such as vom iting and 
cardiac fa ilu re  (which may predispose to acute tubular necrosis), recovery 
does not occur. Second, Mamdani et al (99) suggest that o liguria at 
presentation may favour a good prognosis. Our findings support his 
observation. Four o f our patients were o liguric at presentation or became 
so shortly afterwards; all have recovered. Three were never o liguric ; 1 
recovered and 2 did not. O liguria may herald the development o f acute 
tubular necrosis, and thus be an indication o f a reversible component o f the 
renal fa ilure. Third, the period during which our patients required 
peritoneal dialysis before recovery was sim ila r to that of patients w ith
simple acute tubular necrosis. A second phase o f slower recovery, which 
lasted up to  twelve months, may have been due to  the healing o f the 
arteria l lesions (150) and increasing perfusion and hypertrophy o f the 
remaining nephrons.
The fina l observation in support o f a two stage pathogenetic 
mechanism is the fa te  of the patients w ith malignant essential hypertension 
who are described in the next study. Most o f these patients presented w ith  
malignant hypertension and renal fa ilu re  which was not severe enough to 
require immediate dialysis. The changes in the ir serum creatinine over a 
period of at least eighteen months are shown in Figure 11. Whereas a 
serum creatinine o f less than 300 umol/1 was usually associated w ith  a good 
prognosis, patients w ith  in itia l creatinine of more than 300 umol/1 fa ired 
badly. This experience is broadly sim ilar to that o f others (3,7,94,111) and 
suggests that in malignant hypertension, irreversible renal damage probably 
occurs by the tim e the creatinine concentration has risen above 300 pmol/1 
unless acute renal fa ilu re  is superimposed. Thus, the five  patients who 
recovered renal function in our series may have had renal fa ilu re  caused by 
hypertension up to this level and thereafter developed acute tubular necrosis 
and oliguria. This speculation is supported by the degree o f recovery which 
occurred since a ll patients had a creatinine o f 350 umol/1 or less at the ir 
last v is it.
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STUDY 8: RENA L OUTCOME OF M A LIG N A N T HYPERTENSION:
DIFFERENCES BETWEEN PATIENTS W ITH ESSENTIAL  
H YPERTENSIO N, RENAL VASCULAR A ND RENAL PA REN C HYM A L  
DISEASE 
Introduction
The previous paper described the changes in renal function during 
follow-up o f 7 patients who presented w ith  malignant essential hypertension 
and acute renal fa ilu re . Four o f these patients belonged to  the main cohort 
of 139 malignant hypertensives, and 3 were identified  by case sheet review 
of other patients at the Royal In firm ary in Glasgow. Five o f the 7 showed 
significant and sustained improvement in renal function fo llow ing a period o f 
dialysis and meticulous control of blood pressure. To determine whether 
there were other circumstances in which long term  improvement of renal 
function may occur, we examined the changes in renal function o f all other 
members o f the cohort.
Methods
Patients included in this analysis were those in whom a confident 
diagnosis o f essential hypertension, renovascular disease, chronic 
glomerulonephritis or in te rs titia l nephropathy had been made, and fo r whom 
serial measurements of serum creatinine were available. Patients whose 
follow-up was less than one year were excluded, unless advancing renal 
fa ilu re  had led to the ir death.
Results
The renal outcome of patients w ith  renal parenchymal disease was 
poor despite treatm ent w ith  antihypertensive drugs (Fig 10). Nine o f 12 
patients w ith  in te rs titia l nephropathy and a ll 13 patients w ith  chronic 
glomerulonephritis progressed to end stage renal fa ilu re  during the course o f 
the study. By contrast, those who presented w ith malignant hypertension 
and who had arteriographic evidence of renovascular disease were more
like ly to maintain renal function during treatm ent. Only 3 o f 17 patients 
had evidence o f progressive renal fa ilu re : a 51 year old man w ith  b ila tera l 
renal a rte ry stenosis who died o f congestive cardiac fa ilu re  w ith  serum 
creatinine 884 u mol/1, a 61 year old mana also w ith b ila te ra l renal artery 
stenosis who died of a stroke w ith  serum creatinine 600 umol/1, and a 48 
year old woman whose cause o f death was meningitis a fte r a storm y course 
on peritoneal dialysis.
O f the 83 patients w ith  malignant essential hypertension, 70 fu lfille d  
the c rite ria  fo r this analysis (Fig 11). Five o f these had acute renal fa ilu re  
(4 o f the 5 were considered in more detail in Study 7). F ifteen had serum 
creatinine greater than 300 n mol/1 but did not require dialysis immediately, 
and 50 had serum creatinine less than 300 jimol/1 when f ir s t  seen. The 
renal outcome of these patients has been shown in figure 11. D eterioration 
o f renal function to long term dialysis or death occurred in 1 (20%) patient 
w ith  acute renal fa ilu re , 11 (73%) patients who did not require dialysis 
immediately and 4 (8%) patients w ith  in it ia l serum creatinine <300 umol/1, 
respectively. These data suggest there may be three groups o f patients 
w ith  the malignant phase o f essential hypertension, whose renal prognosis is 
quite d iffe rent.
Discussion
Renal function of patients w ith  malignant hypertension does not 
necessarily deteriorate during treatm ent, unless associated w ith  underlying 
renal disease or w ith  significant renal impairment at presentation. This 
was firs t established by Woods & B lythe in (109), and has since been 
confirmed by a number o f other authors (110-115). In the series reported 
by Pohl et al (111) e ffective  antihypertensive therapy improved renal 
function in patients who had survived fo r six months, whose in itia l 
creatinine clearance was >8 mls/min and in whom there was no in trins ic  
progressive renal disease. Follow-up extended to 43 months in this study
and the improvement in renai function was maintained during this tim e. 
H e riitz  e t al (115) evaluated renal function in a group o f 24 patients w ith  
malignant essential hypertension presenting between 1969 and 1979. Renal 
function deteriorated in 5 o f 6 patients whose in itia l serum creatinine was 
>300 umol/1, but improved or remained stable in 16 o f 18 patients whose 
creatinine was <300 u mol/1 when f irs t seen.
Our own results are sim ilar in many respects. The renal function o f 
patients w ith  renal parenchymal disease almost invariably deteriorated during 
long term  follow-up, irrespective of blood pressure control, such that a ll 
patients w ith  glomerulonephritis and most w ith  in te rs titia l nephropathy had 
developed end stage renal fa ilure by the end of the study. I t  seems like ly  
that deterioration o f renal function in these patients simply represents the 
natural history of a progressive underlying disease. By contrast, renal 
function in malignant hypertension associated w ith renovascular disease 
deteriorated in 3 o f 17 patients only (Fig 10). Overall survival in these 
patients was no be tte r, however, than in the renal parenchymal group (see 
Table 9, Study 9), presumably as a result o f widespread atheromatous 
disease affecting  not only the renal but also the coronary and cerebral 
circulations.
The renal outcome o f patients considered to have the malignant phase 
o f essential hypertension is shown in Figure 11, in which there appear to be 
three groups o f patients, each w ith  a d iffe ren t renal prognosis. F irs t, 
patients who have serum creatinine concentration below 300 umol/1 at the 
tim e o f presentation, most of whom do well w ith  e ffective  antihypertensive 
therapy. Second, patients who present w ith  chronic renal fa ilu re  but do not 
require dialysis immediately. These patients are less like ly  to maintain or 
recover renal function except possibly in the short term (94) and progression 
to end stage renal fa ilu re  is common. Third, there is a small group w ith  
acute renal fa ilu re  (as discussed in Study 7). These patients rarely give a
past history of renai im pairm ent. The only certain way to establish the 
diagnosis, and to  exclude underlying renal disease, is by renal biopsy. In 
this series of 70 consecutive patients w ith  malignant essential hypertension, 
five  presented w ith  acute renal fa ilu re , and in four o f these renal function 
improved significantly fo llow ing a period of dialysis and meticulous blood 
pressure control. The im plication o f these findings is tha t in malignant 
essential hypertension, irreversible renal damage w ill usually have occurred 
by the time the serum creatinine concentration exceeds 300 p mol/1, unless 
acute renal fa ilu re  is superimposed.
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FIGURE 10 Changes in renal function during follow-up o f malignant 
hypertension in patients w ith renovascular disease, chronic glomerulonephritis 
and in te rs titia l nephropathy. The values shown are in it ia l and fin a l serum 
creatinine concentration. A t least 1 year separates each pair o f 
measurements except when rapidly advancing renal fa ilu re  led to a patients 
death. These data represent long term rather than short term  changes in 
renal function therefore.
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FIGURE 11 Changes in renal function during follow-up of patients w ith 
malignant phase of essential hypertension. C rite ria  for inclusion were as 
for figure 10. Closed circles represent patients whose serum creatinine was 
below 300 umol/1 at time of presentation (n=50). Open circles represent 
patients w ith renal fa ilure who did not require dialysis immediately (n=15). 
Closed triangles are patients w ith syndrome of malignant hypertension and 
acute renal fa ilure (n=5).
STUDY 9 : AN  AN ALYSIS  OF SURVIVAL IN  M A L IG N A N T
HYPERTEN SIO N.
Introduction
The prognosis fo r patients w ith  malignant hypertension has improved 
considerably since the advent o f e ffective  antihypertensive therapy (3,52,116) 
but the extent to which the ir m o rta lity  s til l exceeds tha t o f matched 
controls, and the cause of tha t excess m orta lity , has never been determined. 
A prelim inary report o f our study has been published (4).
Methods
The study was in three parts. In the firs t part, factors influencing 
m orta lity  among patients w ith  malignant hypertension were assessed both by 
univariate analysis and by m ultivaria te  analysis using the Cox proportional 
hazards model (129).
In the second part, survival o f the 139 malignant hypertensives from 
diagnosis to 1.4.84 was calculated by life  table analysis, and was compared 
w ith  tha t o f two control populations: w ith  139 non malignant hypertensives 
who attended the Glasgow Blood Pressure C linic (117) during the same 
period and were matched individually fo r age, sex, in itia l blood pressure and 
year o f presentation, and w ith  data derived from the general population o f 
Strathclyde (120) at the m id-point o f our study in 1976. Record linkage of 
both groups of hypertensive patients w ith  the Registrar General in Scotland 
ensured tha t when death occurred, the date o f death was no tified  in each 
case even i f  patients were no longer attending a hospital c lin ic , but 
providing tha t death occurred w ith in  the United Kingdom.
In the th ird  part o f the study, the cause of death among patients 
w ith  malignant hypertension, as given by the Registrar General on the death 
ce rtifica te , was compared w ith  that of the 139 matched non malignant 
hypertensives from  the Glasgow c lin ic  and also with an unmatched group 
consisting o f a ll 3783 non malignant hypertensives who attended the Glasgow
clin ic between 1968 and 1983. The average diastolic blood pressure at 
re ferra l to the c lin ic  was rather lower in this group (111 mmHg). Using 
the 9th revision o f the ICD codings, we analysed causes o f death in the 
following categories:
1. IHD ICD CODES 410-414
2. CVD 430-438
3. Other vascular 390-456 excluding above.
4. Renal . 403-404, 580-599.
5. A ll other causes A ll other ICD codes
Results
Univariate analyses
Since the prognosis fo r men and women was sim ila r (Table 9) the 
results fo r both sexes were combined in a ll the analyses which fo llow . Five 
year survival fo r  the Glasgow patients w ith  malignant hypertension is shown 
in figure 12 together w ith  that of selected h istorica l controls. Survival in 
Glasgow was better in the second than in the f irs t ha lf o f our study, and 
better when compared w ith  that of patients studied in an earlier period. 
Part o f the improvement may have been due to the greater use o f dialysis 
and transplantation, and part to more e ffec tive  control o f blood pressure. 
When the data were reanalysed on the assumption tha t dialysis was not 
available and that a patient requiring dialysis would have died, five  year 
survival was reduced from  63% to 51%.
The benefit o f good blood pressure control may be even greater. 
Five year survival in patients whose achieved blood pressure was be tte r than 
average was 85%, and worse than average 29%, although this does not 
exclude the possibility tha t patients like ly  to die have pressure which is 
more d if f ic u lt to control. Also the form of our analysis has the drawback 
that the assessment o f blood pressure achieved during treatm ent was based 
on the last measurement o f blood pressure before death, or before 1.4.84.
An alternative would be to assess blood pressure control at fixed intervals 
from  the tim e o f presentation fo r each patient, but since 17 of the 54 
deaths among malignant hypertensives occurred w ith in 6 months, and 22
w ithin  1 year o f presentation, there are objections to this approach also.
M orta lity  was increased in patients w ith secondary hypertension, in 
the presence of renal fa ilu re  and in smokers (Table 9), but not by
papilloedema when b ila te ra l re tina l haemorrhages and exudates were already 
present (Study 2). Women whose malignant hypertension was thought to 
have been precipitated by the oral contraceptive p ill survived longer than 
women who were not taking the p ill at presentation (Study 4). Survival was 
not related to the source o f re fe rra l: local patients had a s im ilar outcome
to those referred to  us from  outside Glasgow (Table 9).
M ultivaria te  analyses
M ultivaria te analyses were then performed using the Cox proportional 
hazards model to examine the possibility that a risk identified by univariate 
analysis m ight be related only ind irectly  to outcome. I t  was possible fo r 
example that the blood pressure o f patients presenting before 1976 was less 
well controlled by drugs than that o f those who developed malignant 
hypertension a fte r 1976: an association between survival and year o f 
presentation might simply re fle c t a stronger association between survival 
and blood pressure therefore.
M ultivariate analysis o f data available at diagnosis indicated tha t the 
single most useful predictor o f risk was in itia l serum creatinine (pO.OOl) 
(Table 10). The higher the serum creatinine at the onset o f malignant 
phase, the more like ly were patients to die. Patients presenting before 
1976, those w ith secondary hypertension and, as expected, those who were 
older also had s ign ificantly increased m orta lity . By contrast, there was no 
evidence that male sex, cigarette smoking, papilloedema or the height o f 
the in itia l blood pressure affected prognosis adversely a fte r contro lling fo r
the factors mentioned above.
When the m ultivaria te  analysis was repeated to  include blood pressure 
achieved during treatm ent (Table 10), only pressure during treatm ent and 
in itia l serum creatinine were related independently to outcome. A fte r
controlling fo r these factors, year o f presentation, underlying cause and age 
ceased to  be of importance prognostically.
Comparison w ith  control populations
Figure 13 shows that despite the improved prognosis o f patients w ith  
malignant hypertension, m orta lity  s til l exceeds that in non malignant 
hypertensives matched fo r age, sex, in it ia l diastolic blood pressure and year 
o f presentation, by a facto r of approximately two; also tha t non malignant 
hypertensives o f this severity have a much reduced life  expectancy when 
compared w ith  the general population from  which they are derived. This 
comparison was the basis of another study o f mine (117) which is not
detailed in this thesis as it  concerned mainly non malignant hypertension.
Patients w ith  the malignant phase o f essential hypertension and in it ia l 
serum creatinine less than 300 umol/1 had a re la tive ly  good prognosis (80% 
5-year survival, 60% 10-year survival) approaching that o f non malignant
hypertensive controls. This observation is important because nearly ha lf o f
our patients (n=64) belonged to this good prognosis category.
Analysis o f the cause of death
F ifty -fo u r patients w ith  malignant hypertension (27 males) and 34 age, 
sex and pressure matched controls from  the Glasgow Blood Pressure C lin ic  
w ith non-malignant hypertension (21 males) died between presentation and 
1.4.84. Between 1968 and 1.1.83, 750 (450 male) o f 3783 non-malignant 
hypertensives attending the Glasgow c lin ic  died. The principal cause o f 
death among each o f these groups, classified according to the Registrar 
General code, is shown in Table 11. Renal fa ilu re  was the commonest 
ce rtified  cause of death among patients w ith malignant hypertension.
Stroke was the commonest cause among severe but non-malignant 
hypertensives, and myocardial in farction the commonest among non- 
malignant hypertensives generally. Proportionately, renal deaths were 3 and 
9-times more common among patients w ith  malignant hypertension than 
the ir control groups respectively. Case record review showed tha t uraemia 
itse lf was not the usual cause o f death in these patients, confirm ing that
most patients die w ith  renal fa ilu re  but not d irectly  because o f it .
However, i f  the cause o f death was assumed to be "renal fa ilu re ”  when the
serum creatinine was greater than 1000 umol/1, or the patient had been 
accepted fo r dialysis or transplantation, then the proportion o f malignant 
hypertensives dying w ith  renal fa ilu re  was greater, not less, than tha t given 
by the analysis o f the ir death ce rtifica tes. No fewer than 29 (54%) of
malignant hypertensive decedents fu lf ille d  one or other o f these c rite ria . 
These data are consistent w ith the observation (Table 10) th a t high in it ia l 
serum creatinine concentration affects prognosis adversely.
D iscussion
This analysis o f survival in malignant hypertension is based on a 
series o f 139 cases seen in 15 years. Record linkage w ith  the Registrar 
General ensured completeness o f m orta lity  data, and comparison w ith  a 
matched group of non malignant hypertensives was possible because of the 
existence of a computerised blood pressure c lin ic , the Glasgow Blood 
Pressure C llin ic  (117) in the same c ity  at the same tim e. Thus we had an 
unusual opportunity to  assess factors influencing m orta lity  in patients w ith  
malignant hypertension, and to determine how fa r m o rta lity  in our patients 
exceeded that o f the hypertensive population from  which they were derived.
Renal fa ilu re  has long been regarded as the most serious 
manifestation o f malignant hypertension (52,109-115) and our findings suggest 
tha t this statement is as true now as i t  was before the advent o f e ffec tive  
antihypertensive drugs and renal dialysis. O f the other factors examined by
3tep-wise m ultip le regression, only blood pressure achieved during treatm ent 
appeared to  bear any relation to subsequent m orta lity . Surprisingly, neither 
cigarette smoking nor the presence o f papilloedema were related 
independently to  outcome. The form er is interesting since we (18) and 
others (19-21) have shown tha t patients w ith  malignant hypertension are 
more like ly  to  smoke. The la tte r  supports recommendations (8) tha t the 
definition of malignant hypertension should include patients whose fundi 
show b ila tera l re tina l haemorrhages and exudates only. Our findings also 
suggest tha t the improved survival in patients developing malignant 
hypertension during the second ha lf o f the study was due to  improved blood 
pressure control, since the relationship between year of onset o f malignant 
hypertension and m orta lity  disappeared a fte r controlling fo r achieved 
pressure.
Comparison o f survival at 5 and 10 years by life  table analysis 
showed that patients w ith malignant hypertension were s t il l tw ice  as like ly  
to die as non malignant controls matched fo r age, sex, in it ia l pressure and 
year of presentation. While improved survival may be the result o f more 
e ffective  antihypertensive drugs and the wider use o f renal dialysis, the 
persistently high m orta lity  is like ly  to re fle c t patients w ith  underlying renal 
disease or significant renal impairm ent when firs t seen. These conclusions 
are supported by an analysis o f the causes of death in patients w ith  
malignant hypertension and controls. Fortunately the m a jo rity  o f patients 
w ith  malignant hypertension have the malignant phase o f essential 
hypertension and renal function th a t is only m ild ly or moderately impaired, 
and in these a 10 year survival o f at least 60% may be expected.
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CONCLUSIONS
Despite suggestions that the incidence o f malignant hypertension is 
declining in Europe and North America (1), this study suggests tha t i t  is not 
yet a rare disease in the West o f Scotland. Indeed its  persistence in these 
parts has perm itted us to conduct a number o f analyses which would not 
have been possible had the number of new cases presenting each year been 
less.
The firs t analysis was an assesssment o f re tina l changes showing that 
papilloedema is of no additional prognostic importance in hypertensive 
patients who already have b ila tera l re tina l haemorrhages and exudates. 
Hopefully this w ill settle the old argument concerning the degree of 
retinopathy required to establish a diagnosis.
The association of malignant hypertension w ith  cigarette  smoking had 
not been described before. We are unable to  say on this evidence alone, 
whether smoking predisposes to the malignant phase in patients who are 
already hypertensive, or whether some other fac to r predisposes both to 
smoking and to malignant hypertension. Further studies w ill be required to 
resolve this question. There is p len tifu l evidence to show tha t smoking does 
not cause benign phase hypertension.
The nature of the association between the oral contraceptive p ill and 
malignant hypertension is clearer, particularly in patients who were known 
to be normotensive before starting the p ill and developed the malignant 
phase shortly afterwards. Thus, our results suggest that oral contraceptives 
may be a re la tive ly common cause o f malignant hypertension in women o f 
childbearing age in whom the condition is otherwise rare. Fortunately, i f  
the p ill is stopped and underlying renal disease can be excluded, the long 
term prognosis fo r such patients can be excellent.
The f if th  analysis was a test of the hypothesis that low grade 
coagulopathy is a necessary step in the transition from the benign to
malignant phase. Our finding tha t carefu lly matched controls had sim ila r 
haemostatic abnormalities indicates there may be an a lternative explanation, 
namely that abnormal coagulation may also be a consequence of the 
malignant phase.
The remaining four analyses were concerned prim arily w ith  treatm ent 
and outcome. Atenolol and nifedipine retard were compared in a 
randomised tr ia l of treatm ent in 20 black patients w ith  malignant 
hypertension, and both were found to be e ffective  and safe when given as 
in it ia l therapy. These results re-emphasize that most patients w ith  
malignant hypertension can be managed w ithout recourse to parenteral 
therapy.
The two studies on renal outcome in malignant hypertension suggest 
that the heterogeneity of the renal response to treatm ent is determined 
prim arily  by the underlying renal pathology. Thus, in glomerulonephritis and 
in te rs titia l nephropathy, deterioration o f renal function during long term  
treatm ent is like ly to represent the natural history o f a progressive 
underlying disease. By contrast, in patients w ith  the. malignant phase o f 
essential hypertension, renal fa ilu re  is an uncommon outcome unless the 
in itia l serum creatinine exceeds 300 umol/1.
An im portant exception to this general rule is the patient w ith  
malignant essential hypertension and acute renal fa ilure. Many o f such 
patients w ill show significant improvement in renal function fo llow ing 
treatm ent w ith  antihypertensive drugs and peritoneal dialysis. This diagnosis 
should be considered therefore in o liguric  patients w ith marked vascular 
changes but well preserved glomeruli on renal biopsy.
In the fina l analysis of this thesis, malignant hypertensives were 
shown to have an improved survival compared w ith  sim ilar patients studied 
in an earlier period, but a higher m o rta lity  than non-malignant hypertensives 
matched fo r age, sex, in itia l pressure and year of presentation. Improved
survival may be, at least in part, the result o f more e ffective  
antihypertensive drugs and the wider use o f renal dialysis, while the 
persistently high m orta lity  is like ly to re fle c t underlying renal disease or 
significant renal impairment when patients are f irs t  seen.
What then of the future? The reason why some patients w ith  
diastolic pressures greater than 130 mmHg enter the malignant phase, while 
others do not has s t i l l  to be determined. So too has the re lative 
importance o f genetic and socioeconomic factors in the pathogenesis o f the 
disease. Not enough is known of the effects o f d iffe ren t antihypertensive 
drugs on cerebral blood flow at d iffe rent a rte ria l pressures fo r a confident 
conclusion concerning the ideal rate of reduction o f pressure when patients 
are f irs t seen. I t  is also unclear whether fu rthe r improvements in survival 
fo r patients w ith  significant renal impairment can be expected. The 
problem in the United Kingdom is that we no longer see enough malignant 
hypertension, even in the West o f Scotland, to answer these questions. The 
burden of work must then inevitably fa ll on units tha t do see i t ,  probably 
those in A fr ica  and South America (2).
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